Binding molecules specific for CD73 and uses of the binding molecules

Abstract

Binding molecules specific for CD73 and uses of the binding molecules. Specifically, provided are isolated antibodies and antigen-binding portions of the isolated antibodies that bind to and inhibit CD73 activity, and uses of the isolated antibodies or antigen-binding portions thereof in the treatment of disease; also provided are nucleic acid molecules encoding the isolated antibodies or antigen-binding portions thereof, expression vectors for expressing the isolated antibodies or antigen-binding portions thereof, host cells, and preparation methods.

Description

[Technical field]

[0001] The present invention relates to an isolated antibody or antigen-binding fragment thereof that specifically binds to CD73, the present invention also relates to the use of the isolated antibody or antigen-binding fragment thereof in the treatment of disease, and the present invention relates to methods of treatment with the isolated antibody or antigen-binding fragment thereof. [Background technology]

[0002] CD73 (ecto-5'-nucleotidase) is a membrane-bound / free protein with a size of approximately 70 kDa, consisting of N-terminal and C-terminal subunits and a flexible linker. The C-terminus is anchored to the cell membrane via glycosylphosphatidylinositol (GPI). CD73 exerts its enzymatic activity through an open / closed conformational switch (Knapp, K. et al. (2012), Structure, 20(12), 2161-2173). In the adenosine pathway, CD73 can continue to hydrolyze AMP produced by CD39 to adenosine. Adenosine exerts various immunosuppressive effects, such as suppressing the proliferation of CD4+ and CD8+ T cells, suppressing NK cell activity, and promoting Treg proliferation.

[0003] CD73 is highly expressed in various tumors, including gastric cancer, triple-negative breast cancer, non-small cell adenocarcinoma, rectal adenocarcinoma, colon cancer, renal cell carcinoma, ovarian cancer, prostate cancer, oral squamous cell carcinoma, and head and neck squamous cell carcinoma, and it has been widely reported that high CD73 expression was associated with poor prognosis (Vijayan, D. et al., (2017), Nature reviews Cancer, 17, 709). Increased expression of CD73 in the tumor microenvironment was associated with tumor growth, metastasis, angiogenesis, and poor survival in patients (Allard, B. et al., (2017), Immunological reviews, 276 (1), 121-144). High expression of CD73 leads to increased adenosine, which activates tumor-intrinsic and host-mediated tumor-promoting mechanisms and suppresses tumor immunity by limiting immune cell infiltration and cytotoxicity and cytokine (e.g., interferon) production, resulting in strong immunosuppression (Ohta, A. et al., (2016), Front Immunol, 7, 109). Immunosuppression is a typical feature of cancer, and it is important to overcome inhibitory barriers. Therefore, inhibiting CD73 is a very promising therapeutic direction to inhibit the production of adenosine in the tumor microenvironment, thereby activating immunity and inhibiting tumor growth.

[0004] Although antibodies can inhibit the enzymatic activity of CD73 by antagonizing the allosteric CD73 to its active form, there are no reports of antibodies that can directly bind to the CD73 active site and inhibit its enzymatic activity. Meanwhile, CD73 is a very potential therapeutic target, but more research is needed to validate the prognosis of CD73 targeting and develop related drugs and combination therapies. Summary of the Invention

[0005] The present invention provides isolated antibodies or antigen-binding fragments that specifically bind to CD73 and their uses in treating diseases.

[0006] In one aspect, the invention provides an isolated antibody or antigen-binding fragment thereof, comprising a heavy chain variable region comprising HCDR1, HCDR2, HCDR3; and a light chain variable region comprising LCDR1, LCDR2, LCDR3: (a) HCDR1 comprises an amino acid sequence selected from the group consisting of SEQ ID NOs: 5, 18, 31, 43 and 56, and conservative modifications thereof; (b) HCDR2 comprises an amino acid sequence selected from the group consisting of SEQ ID NOs: 6, 19, 32, 44 and 57, and conservative modifications thereof; (c) HCDR3 comprises an amino acid sequence selected from the group consisting of SEQ ID NOs: 7, 20, 33, 45 and 58, and conservative modifications thereof; (d) LCDR1 comprises an amino acid sequence selected from the group consisting of SEQ ID NOs: 10, 23, 36, 48 and 61, and conservative modifications thereof; (e) LCDR2 comprises an amino acid sequence selected from the group consisting of SEQ ID NOs: 11, 24, 37, 49, and 62, and conservative modifications thereof; and (f) LCDR3 comprises an amino acid sequence selected from the group consisting of SEQ ID NOs: 12, 25, 38, 50 and 63, and conservative modifications thereof. An isolated antibody or antigen-binding fragment thereof is provided.

[0007] In some embodiments, the isolated antibody or antigen-binding fragment thereof comprises: 1) (a) an HCDR1 comprising SEQ ID NO:5, (b) an HCDR2 comprising SEQ ID NO:6, (c) an HCDR3 comprising SEQ ID NO:7, (d) an LCDR1 comprising SEQ ID NO:10, (e) an LCDR2 comprising SEQ ID NO:11, and (f) an LCDR3 comprising SEQ ID NO:12; 2) (a) an HCDR1 comprising SEQ ID NO: 18, (b) an HCDR2 comprising SEQ ID NO: 19, (c) an HCDR3 comprising SEQ ID NO: 20, (d) an LCDR1 comprising SEQ ID NO: 23, (e) an LCDR2 comprising SEQ ID NO: 24, and (f) an LCDR3 comprising SEQ ID NO: 25; 3) (a) an HCDR1 comprising SEQ ID NO:31, (b) an HCDR2 comprising SEQ ID NO:32, (c) an HCDR3 comprising SEQ ID NO:33, (d) an LCDR1 comprising SEQ ID NO:36, (e) an LCDR2 comprising SEQ ID NO:37, and (f) an LCDR3 comprising SEQ ID NO:38; 4) (a) an HCDR1 comprising SEQ ID NO: 43, (b) an HCDR2 comprising SEQ ID NO: 44, (c) an HCDR3 comprising SEQ ID NO: 45, (d) an LCDR1 comprising SEQ ID NO: 48, (e) an LCDR2 comprising SEQ ID NO: 49, and (f) an LCDR3 comprising SEQ ID NO: 50; or 5) (a) an HCDR1 comprising SEQ ID NO: 56, (b) an HCDR2 comprising SEQ ID NO: 57, (c) an HCDR3 comprising SEQ ID NO: 58, (d) an LCDR1 comprising SEQ ID NO: 61, (e) an LCDR2 comprising SEQ ID NO: 62, and (f) an LCDR3 comprising SEQ ID NO: 63.

[0008] In some embodiments, the isolated antibody or antigen-binding fragment thereof comprises: (a) an HCDR1 comprising SEQ ID NO:5, (b) an HCDR2 comprising SEQ ID NO:6, (c) an HCDR3 comprising SEQ ID NO:7, (d) an LCDR1 comprising SEQ ID NO:10, (e) an LCDR2 comprising SEQ ID NO:11, and (f) an LCDR3 comprising SEQ ID NO:12.

[0009] In some embodiments, the isolated antibody or antigen-binding fragment thereof comprises: (a) an HCDR1 comprising SEQ ID NO: 18, (b) an HCDR2 comprising SEQ ID NO: 19, (c) an HCDR3 comprising SEQ ID NO: 20, (d) an LCDR1 comprising SEQ ID NO: 23, (e) an LCDR2 comprising SEQ ID NO: 24, and (f) an LCDR3 comprising SEQ ID NO: 25.

[0010] In some embodiments, the isolated antibody or antigen-binding fragment thereof comprises: (a) an HCDR1 comprising SEQ ID NO: 31, (b) an HCDR2 comprising SEQ ID NO: 32, (c) an HCDR3 comprising SEQ ID NO: 33, (d) an LCDR1 comprising SEQ ID NO: 36, (e) an LCDR2 comprising SEQ ID NO: 37, and (f) an LCDR3 comprising SEQ ID NO: 38.

[0011] In some embodiments, the isolated antibody or antigen-binding fragment thereof comprises: (a) an HCDR1 comprising SEQ ID NO: 43, (b) an HCDR2 comprising SEQ ID NO: 44, (c) an HCDR3 comprising SEQ ID NO: 45, (d) an LCDR1 comprising SEQ ID NO: 48, (e) an LCDR2 comprising SEQ ID NO: 49, and (f) an LCDR3 comprising SEQ ID NO: 50.

[0012] In some embodiments, the isolated antibody or antigen-binding fragment thereof comprises: (a) an HCDR1 comprising SEQ ID NO: 56, (b) an HCDR2 comprising SEQ ID NO: 57, (c) an HCDR3 comprising SEQ ID NO: 58, (d) an LCDR1 comprising SEQ ID NO: 61, (e) an LCDR2 comprising SEQ ID NO: 62, and (f) an LCDR3 comprising SEQ ID NO: 63.

[0013] In some embodiments, the isolated antibody or antigen-binding fragment thereof comprises: (i) a heavy chain variable region (VH) comprising an amino acid sequence having at least 85% identity to an amino acid sequence selected from the group consisting of SEQ ID NOs: 3, 16, 29, 41, 54, 66, 67, 76, 77, and 78, and conservative modifications thereof; and (ii) a light chain variable region (VL) comprising an amino acid sequence having at least 85% identity to an amino acid sequence selected from the group consisting of SEQ ID NOs: 8, 21, 34, 46, 59, 68, 69, 70, 79 and 80, and conservative modifications thereof.

[0014] In some embodiments, the heavy chain variable region comprises an amino acid sequence that is at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical to a heavy chain variable region selected from group (i), and the light chain variable region comprises an amino acid sequence that is at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical to a light chain variable region selected from group (ii).

[0015] In some embodiments, the isolated antibody or antigen-binding fragment thereof comprises: 1) a heavy chain variable region (VH) comprising an amino acid sequence having at least 85% homology to the amino acid sequence of SEQ ID NO: 3, and a light chain variable region (VL) comprising an amino acid sequence having at least 85% homology to the amino acid sequence of SEQ ID NO: 8; 2) a heavy chain variable region (VH) comprising an amino acid sequence having at least 85% homology to the amino acid sequence of SEQ ID NO: 16, and a light chain variable region (VL) comprising an amino acid sequence having at least 85% homology to the amino acid sequence of SEQ ID NO: 21; 3) a heavy chain variable region (VH) comprising an amino acid sequence having at least 85% homology to the amino acid sequence of SEQ ID NO: 29, and a light chain variable region (VL) comprising an amino acid sequence having at least 85% homology to the amino acid sequence of SEQ ID NO: 34; 4) a heavy chain variable region (VH) comprising an amino acid sequence having at least 85% homology to the amino acid sequence of SEQ ID NO: 41, and a light chain variable region (VL) comprising an amino acid sequence having at least 85% homology to the amino acid sequence of SEQ ID NO: 46; 5) a heavy chain variable region (VH) comprising an amino acid sequence having at least 85% homology to the amino acid sequence of SEQ ID NO: 54, and a light chain variable region (VL) comprising an amino acid sequence having at least 85% homology to the amino acid sequence of SEQ ID NO: 59; 6) a heavy chain variable region (VH) comprising an amino acid sequence having at least 85% homology to the amino acid sequence of SEQ ID NO: 66, and a light chain variable region (VL) comprising an amino acid sequence having at least 85% homology to the amino acid sequence of SEQ ID NO: 68; 7) a heavy chain variable region (VH) comprising an amino acid sequence having at least 85% homology to the amino acid sequence of SEQ ID NO: 66, and a light chain variable region (VL) comprising an amino acid sequence having at least 85% homology to the amino acid sequence of SEQ ID NO: 69; 8) a heavy chain variable region (VH) comprising an amino acid sequence having at least 85% homology to the amino acid sequence of SEQ ID NO: 66, and a light chain variable region (VL) comprising an amino acid sequence having at least 85% homology to the amino acid sequence of SEQ ID NO: 70; 9) a heavy chain variable region (VH) comprising an amino acid sequence having at least 85% homology to the amino acid sequence of SEQ ID NO: 67, and a light chain variable region (VL) comprising an amino acid sequence having at least 85% homology to the amino acid sequence of SEQ ID NO: 68; 10) a heavy chain variable region (VH) comprising an amino acid sequence having at least 85% homology to the amino acid sequence of SEQ ID NO: 67, and a light chain variable region (VL) comprising an amino acid sequence having at least 85% homology to the amino acid sequence of SEQ ID NO: 69; 11) a heavy chain variable region (VH) comprising an amino acid sequence having at least 85% homology to the amino acid sequence of SEQ ID NO: 67, and a light chain variable region (VL) comprising an amino acid sequence having at least 85% homology to the amino acid sequence of SEQ ID NO: 70; 12) a heavy chain variable region (VH) comprising an amino acid sequence having at least 85% homology to the amino acid sequence of SEQ ID NO: 76, and a light chain variable region (VL) comprising an amino acid sequence having at least 85% homology to the amino acid sequence of SEQ ID NO: 79; 13) a heavy chain variable region (VH) comprising an amino acid sequence having at least 85% homology to the amino acid sequence of SEQ ID NO: 76, and a light chain variable region (VL) comprising an amino acid sequence having at least 85% homology to the amino acid sequence of SEQ ID NO: 80; 14) a heavy chain variable region (VH) comprising an amino acid sequence having at least 85% homology to the amino acid sequence of SEQ ID NO: 77, and a light chain variable region (VL) comprising an amino acid sequence having at least 85% homology to the amino acid sequence of SEQ ID NO: 79; 15) a heavy chain variable region (VH) comprising an amino acid sequence having at least 85% homology to the amino acid sequence of SEQ ID NO: 77, and a light chain variable region (VL) comprising an amino acid sequence having at least 85% homology to the amino acid sequence of SEQ ID NO: 80; 16) a heavy chain variable region (VH) comprising an amino acid sequence having at least 85% homology to the amino acid sequence of SEQ ID NO: 78, and a light chain variable region (VL) comprising an amino acid sequence having at least 85% homology to the amino acid sequence of SEQ ID NO: 79; 17) A heavy chain variable region (VH) comprising an amino acid sequence having at least 85% homology to the amino acid sequence of SEQ ID NO: 78, and a light chain variable region (VL) comprising an amino acid sequence having at least 85% homology to the amino acid sequence of SEQ ID NO: 80.

[0016] In some embodiments, an isolated antibody or antigen-binding fragment thereof, wherein the heavy and light chain variable regions comprise amino acid sequences having at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identity to the heavy and light chain variable regions, respectively, selected from the group consisting of 1) to 17).

[0017] In some embodiments, the isolated antibody is an IgG.

[0018] In some embodiments, the isolated antibody is an IgG1, IgG2 or IgG4.

[0019] In some embodiments, the isolated antibody is a monoclonal antibody, a chimeric antibody, a humanized antibody, a human engineered antibody, a human antibody, an Fv, a single chain antibody (scFv), a Fab, a Fab', a Fab'-SH or a F(ab'). 2 It is.

[0020] In some embodiments, the isolated antibody or antigen-binding fragment thereof comprises the following heavy and light chains: (I) a heavy chain comprising an amino acid sequence having at least 85% identity to an amino acid sequence selected from the group consisting of SEQ ID NOs: 13, 15, 26, 27, 39, 51, 52, 64, 71, 72, 81, 82, 83, 86, 87, 90, 91, 124, 125, 126, and 127, and conservative modifications thereof; and (II) A light chain comprising an amino acid sequence having at least 85% identity to an amino acid sequence selected from the group consisting of SEQ ID NOs: 14, 28, 40, 53, 65, 73, 74, 75, 84, 85, 88 and 89, and conservative modifications thereof.

[0021] In some embodiments, the heavy chain comprises an amino acid sequence having at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or 100% identity to a heavy chain selected from group (I), and the light chain comprises an amino acid sequence having at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or 100% identity to a light chain selected from group (II).

[0022] In some embodiments, the isolated antibody or antigen-binding fragment thereof comprises: 1) a heavy chain comprising an amino acid sequence having at least 85% homology to the amino acid sequence of SEQ ID NO: 13, and a light chain comprising an amino acid sequence having at least 85% homology to the amino acid sequence of SEQ ID NO: 14; 2) a heavy chain comprising an amino acid sequence having at least 85% homology to the amino acid sequence of SEQ ID NO: 15, and a light chain comprising an amino acid sequence having at least 85% homology to the amino acid sequence of SEQ ID NO: 14; 3) a heavy chain comprising an amino acid sequence having at least 85% homology to the amino acid sequence of SEQ ID NO:26, and a light chain comprising an amino acid sequence having at least 85% homology to the amino acid sequence of SEQ ID NO:28; 4) a heavy chain comprising an amino acid sequence having at least 85% homology to the amino acid sequence of SEQ ID NO:27, and a light chain comprising an amino acid sequence having at least 85% homology to the amino acid sequence of SEQ ID NO:28; 5) a heavy chain comprising an amino acid sequence having at least 85% homology to the amino acid sequence of SEQ ID NO: 39, and a light chain comprising an amino acid sequence having at least 85% homology to the amino acid sequence of SEQ ID NO: 40; 6) a heavy chain comprising an amino acid sequence having at least 85% identity to the amino acid sequence of SEQ ID NO: 51, and a light chain comprising an amino acid sequence having at least 85% identity to the amino acid sequence of SEQ ID NO: 53; 7) a heavy chain comprising an amino acid sequence having at least 85% identity to the amino acid sequence of SEQ ID NO: 52, and a light chain comprising an amino acid sequence having at least 85% identity to the amino acid sequence of SEQ ID NO: 53; 8) a heavy chain comprising an amino acid sequence having at least 85% homology to the amino acid sequence of SEQ ID NO: 64, and a light chain comprising an amino acid sequence having at least 85% homology to the amino acid sequence of SEQ ID NO: 65; 9) a heavy chain comprising an amino acid sequence having at least 85% homology to the amino acid sequence of SEQ ID NO: 71, and a light chain comprising an amino acid sequence having at least 85% homology to the amino acid sequence of SEQ ID NO: 73; 10) a heavy chain comprising an amino acid sequence having at least 85% homology to the amino acid sequence of SEQ ID NO: 71, and a light chain comprising an amino acid sequence having at least 85% homology to the amino acid sequence of SEQ ID NO: 74; 11) a heavy chain comprising an amino acid sequence having at least 85% identity to the amino acid sequence of SEQ ID NO: 71, and a light chain comprising an amino acid sequence having at least 85% identity to the amino acid sequence of SEQ ID NO: 75; 12) a heavy chain comprising an amino acid sequence having at least 85% identity to the amino acid sequence of SEQ ID NO: 72, and a light chain comprising an amino acid sequence having at least 85% identity to the amino acid sequence of SEQ ID NO: 73; 13) a heavy chain comprising an amino acid sequence having at least 85% identity to the amino acid sequence of SEQ ID NO: 72, and a light chain comprising an amino acid sequence having at least 85% identity to the amino acid sequence of SEQ ID NO: 74; 14) a heavy chain comprising an amino acid sequence having at least 85% homology to the amino acid sequence of SEQ ID NO: 72, and a light chain comprising an amino acid sequence having at least 85% homology to the amino acid sequence of SEQ ID NO: 75; 15) a heavy chain comprising an amino acid sequence having at least 85% homology to the amino acid sequence of SEQ ID NO: 81, and a light chain comprising an amino acid sequence having at least 85% homology to the amino acid sequence of SEQ ID NO: 84; 16) a heavy chain comprising an amino acid sequence having at least 85% homology to the amino acid sequence of SEQ ID NO: 81, and a light chain comprising an amino acid sequence having at least 85% homology to the amino acid sequence of SEQ ID NO: 85; 17) a heavy chain comprising an amino acid sequence having at least 85% homology to the amino acid sequence of SEQ ID NO: 82, and a light chain comprising an amino acid sequence having at least 85% homology to the amino acid sequence of SEQ ID NO: 84; 18) a heavy chain comprising an amino acid sequence having at least 85% homology to the amino acid sequence of SEQ ID NO: 82, and a light chain comprising an amino acid sequence having at least 85% homology to the amino acid sequence of SEQ ID NO: 85; 19) a heavy chain comprising an amino acid sequence having at least 85% homology to the amino acid sequence of SEQ ID NO: 83, and a light chain comprising an amino acid sequence having at least 85% homology to the amino acid sequence of SEQ ID NO: 84; 20) a heavy chain comprising an amino acid sequence having at least 85% homology to the amino acid sequence of SEQ ID NO: 83, and a light chain comprising an amino acid sequence having at least 85% homology to the amino acid sequence of SEQ ID NO: 85; 21) a heavy chain comprising an amino acid sequence having at least 85% homology to the amino acid sequence of SEQ ID NO: 90, and a light chain comprising an amino acid sequence having at least 85% homology to the amino acid sequence of SEQ ID NO: 84; 22) a heavy chain comprising an amino acid sequence having at least 85% homology to the amino acid sequence of SEQ ID NO: 90, and a light chain comprising an amino acid sequence having at least 85% homology to the amino acid sequence of SEQ ID NO: 85; 23) a heavy chain comprising an amino acid sequence having at least 85% identity to the amino acid sequence of SEQ ID NO: 91, and a light chain comprising an amino acid sequence having at least 85% identity to the amino acid sequence of SEQ ID NO: 84; 24) a heavy chain comprising an amino acid sequence having at least 85% identity to the amino acid sequence of SEQ ID NO: 91, and a light chain comprising an amino acid sequence having at least 85% identity to the amino acid sequence of SEQ ID NO: 85; 25) a heavy chain comprising an amino acid sequence having at least 85% homology to the amino acid sequence of SEQ ID NO: 86, and a light chain comprising an amino acid sequence having at least 85% homology to the amino acid sequence of SEQ ID NO: 88; 26) a heavy chain comprising an amino acid sequence having at least 85% identity to the amino acid sequence of SEQ ID NO: 86, and a light chain comprising an amino acid sequence having at least 85% identity to the amino acid sequence of SEQ ID NO: 89; 27) a heavy chain comprising an amino acid sequence having at least 85% identity to the amino acid sequence of SEQ ID NO: 87, and a light chain comprising an amino acid sequence having at least 85% identity to the amino acid sequence of SEQ ID NO: 88; 28) a heavy chain comprising an amino acid sequence having at least 85% homology to the amino acid sequence of SEQ ID NO: 87, and a light chain comprising an amino acid sequence having at least 85% homology to the amino acid sequence of SEQ ID NO: 89; 29) a heavy chain comprising an amino acid sequence having at least 85% identity to the amino acid sequence of SEQ ID NO: 124, and a light chain comprising an amino acid sequence having at least 85% identity to the amino acid sequence of SEQ ID NO: 84; 30) a heavy chain comprising an amino acid sequence having at least 85% homology to the amino acid sequence of SEQ ID NO: 124, and a light chain comprising an amino acid sequence having at least 85% homology to the amino acid sequence of SEQ ID NO: 85; 31) a heavy chain comprising an amino acid sequence having at least 85% identity to the amino acid sequence of SEQ ID NO: 125, and a light chain comprising an amino acid sequence having at least 85% identity to the amino acid sequence of SEQ ID NO: 84; or 32) A heavy chain comprising an amino acid sequence having at least 85% homology to the amino acid sequence of SEQ ID NO: 125, and a light chain comprising an amino acid sequence having at least 85% homology to the amino acid sequence of SEQ ID NO: 85.

[0023] In some embodiments, the heavy and light chains comprise amino acid sequences that are at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical to a heavy and light chain variable region, respectively, selected from the group consisting of 1) to 32).

[0024] In another aspect, the present invention provides an isolated antibody or antigen-binding fragment thereof comprising a heavy chain of SEQ ID NO:71 and a light chain of SEQ ID NO:73.

[0025] In yet another aspect, the present invention provides an isolated antibody or antigen-binding fragment thereof comprising a heavy chain consisting essentially of SEQ ID NO:72 and a light chain consisting essentially of SEQ ID NO:74.

[0026] In one aspect, the present invention provides an isolated antibody or antigen-binding fragment thereof comprising a heavy chain of SEQ ID NO:72 and a light chain of SEQ ID NO:75.

[0027] In another aspect, the present invention provides an isolated antibody or antigen-binding fragment thereof comprising a heavy chain consisting essentially of SEQ ID NO:81 and a light chain consisting essentially of SEQ ID NO:85.

[0028] In yet another aspect, the present invention provides an isolated antibody or antigen-binding fragment thereof comprising a heavy chain consisting essentially of SEQ ID NO:82 and a light chain consisting essentially of SEQ ID NO:84.

[0029] In another aspect, the present invention provides an isolated antibody or antigen-binding fragment thereof comprising a heavy chain consisting essentially of SEQ ID NO:83 and a light chain consisting essentially of SEQ ID NO:85.

[0030] In another aspect, the present invention provides an isolated antibody or antigen-binding fragment thereof comprising a heavy chain consisting essentially of SEQ ID NO:124 and a light chain consisting essentially of SEQ ID NO:85.

[0031] In yet another aspect, the present invention provides an isolated antibody or antigen-binding fragment thereof comprising a heavy chain consisting essentially of SEQ ID NO:125 and a light chain consisting essentially of SEQ ID NO:85.

[0032] In some embodiments, the isolated antibody or antigen-binding fragment thereof is an antagonist of CD73 or an antagonist of the 5'-nucleotidase of CD73.

[0033] In some embodiments, the CD73 is human CD73.

[0034] In one aspect, the invention provides a method of reducing adenosine levels in a subject with a tumor, comprising administering a therapeutically effective amount of an isolated antibody or antigen-binding fragment thereof.

[0035] In another aspect, the present invention provides a method of improving a T cell response in a tumor-bearing subject, the method comprising administering a therapeutically effective amount of an isolated antibody or antigen-binding fragment thereof.

[0036] In yet another aspect, the invention provides a method of stimulating an immune response in a subject, the method comprising administering a therapeutically effective amount of the isolated antibody or antigen-binding fragment thereof.

[0037] In some embodiments, the subject is a tumor-bearing subject.

[0038] In some embodiments, the subject has tumor cells that express CD73 and / or a tumor microenvironment that contains CD73.

[0039] In one aspect, the invention provides a method of inhibiting the proliferation of tumor cells in a subject, the method comprising administering to the subject a therapeutically effective amount of an isolated antibody or antigen-binding fragment thereof.

[0040] In another aspect, the invention provides use of the isolated antibody or antigen-binding fragment thereof in the manufacture of a medicament for reducing adenosine levels in a tumor cell and / or the tumor microenvironment.

[0041] In yet another aspect, the invention provides the use of the isolated antibody or antigen-binding fragment thereof in the manufacture of a medicament for stimulating a T cell response in a tumor-bearing subject.

[0042] In one aspect, the invention provides use of the isolated antibody or antigen-binding fragment thereof in the manufacture of a medicament for stimulating an immune response in a subject.

[0043] In some embodiments, the subject is a tumor-bearing subject.

[0044] In some embodiments, the subject has tumor cells that express CD73 and / or a tumor microenvironment that contains CD73.

[0045] In another aspect, the invention provides use of the isolated antibody or antigen-binding fragment thereof in the manufacture of a medicament for inhibiting the growth of tumor cells in a subject.

[0046] In yet another aspect, the present invention provides an isolated antibody or antigen-binding fragment thereof for use in reducing adenosine levels in a tumor cell and / or the tumor microenvironment.

[0047] In one aspect, the invention provides an isolated antibody or antigen-binding fragment thereof for use in stimulating a T cell response in a tumor-bearing subject.

[0048] In another aspect, the invention provides an isolated antibody, or antigen-binding fragment thereof, for use in stimulating an immune response in a subject.

[0049] In some embodiments, the subject is a tumor-bearing subject.

[0050] In some embodiments, the isolated antibody or antigen-binding fragment thereof is provided in a subject having tumor cells that express CD73 and / or a tumor microenvironment that contains CD73.

[0051] In another aspect, the invention provides an isolated antibody, or antigen-binding fragment thereof, for use in inhibiting the growth of a tumor cell in a subject.

[0052] In yet another aspect, the present invention provides a composition of isolated nucleic acid comprising: (I) a first nucleic acid comprising a nucleotide sequence selected from the group consisting of SEQ ID NOs: 4, 17, 30, 42, 55, 92, 93, 102, 103 and 104; (II) a second nucleic acid comprising a nucleotide sequence selected from the group consisting of SEQ ID NOs: 9, 22, 35, 47, 60, 94, 95, 96, 105 and 106.

[0053] In some embodiments, the composition of isolated nucleic acid comprises: 1) a first nucleic acid comprising SEQ ID NO:4 and a second nucleic acid comprising SEQ ID NO:9; 2) a first nucleic acid comprising SEQ ID NO: 17 and a second nucleic acid comprising SEQ ID NO: 22; 3) a first nucleic acid comprising SEQ ID NO:30 and a second nucleic acid comprising SEQ ID NO:35; 4) a first nucleic acid comprising SEQ ID NO:42 and a second nucleic acid comprising SEQ ID NO:47; 5) a first nucleic acid comprising SEQ ID NO:55 and a second nucleic acid comprising SEQ ID NO:60; 6) a first nucleic acid comprising SEQ ID NO:92 and a second nucleic acid comprising SEQ ID NO:94; 7) a first nucleic acid comprising SEQ ID NO: 92 and a second nucleic acid comprising SEQ ID NO: 95; 8) a first nucleic acid comprising SEQ ID NO:92 and a second nucleic acid comprising SEQ ID NO:96; 9) a first nucleic acid comprising SEQ ID NO:93 and a second nucleic acid comprising SEQ ID NO:94; 10) a first nucleic acid comprising SEQ ID NO: 93 and a second nucleic acid comprising SEQ ID NO: 95; 11) a first nucleic acid comprising SEQ ID NO: 93 and a second nucleic acid comprising SEQ ID NO: 96; 12) a first nucleic acid comprising SEQ ID NO: 102 and a second nucleic acid comprising SEQ ID NO: 105; 13) a first nucleic acid comprising SEQ ID NO: 102 and a second nucleic acid comprising SEQ ID NO: 106; 14) a first nucleic acid comprising SEQ ID NO: 103 and a second nucleic acid comprising SEQ ID NO: 105; 15) a first nucleic acid comprising SEQ ID NO: 103 and a second nucleic acid comprising SEQ ID NO: 106; 16) a first nucleic acid comprising SEQ ID NO: 104 and a second nucleic acid comprising SEQ ID NO: 105; or 17) A first nucleic acid comprising SEQ ID NO: 104 and a second nucleic acid comprising SEQ ID NO: 106.

[0054] In one aspect, the present invention provides an expression vector composition comprising: (I) a first expression vector comprising a nucleotide sequence selected from the group consisting of SEQ ID NOs: 4, 17, 30, 42, 55, 92, 93, 102, 103 and 104; (II) A second expression vector comprising a nucleotide sequence selected from the group consisting of SEQ ID NOs: 9, 22, 35, 47, 60, 94, 95, 96, 105 and 106.

[0055] In some embodiments, the expression vector composition comprises: 1) a first expression vector comprising the nucleotide sequence of SEQ ID NO:4, and a second expression vector comprising the nucleotide sequence of SEQ ID NO:9; 2) a first expression vector comprising the nucleotide sequence of SEQ ID NO: 17, and a second expression vector comprising the nucleotide sequence of SEQ ID NO: 22; 3) a first expression vector comprising the nucleotide sequence of SEQ ID NO:30, and a second expression vector comprising the nucleotide sequence of SEQ ID NO:35; 4) a first expression vector comprising the nucleotide sequence of SEQ ID NO:42, and a second expression vector comprising the nucleotide sequence of SEQ ID NO:47; 5) a first expression vector comprising the nucleotide sequence of SEQ ID NO:55, and a second expression vector comprising the nucleotide sequence of SEQ ID NO:60; 6) a first expression vector comprising the nucleotide sequence of SEQ ID NO:92, and a second expression vector comprising the nucleotide sequence of SEQ ID NO:94; 7) a first expression vector comprising the nucleotide sequence of SEQ ID NO:92, and a second expression vector comprising the nucleotide sequence of SEQ ID NO:95; 8) a first expression vector comprising the nucleotide sequence of SEQ ID NO:92, and a second expression vector comprising the nucleotide sequence of SEQ ID NO:96; 9) a first expression vector comprising the nucleotide sequence of SEQ ID NO:93, and a second expression vector comprising the nucleotide sequence of SEQ ID NO:94; 10) a first expression vector comprising the nucleotide sequence of SEQ ID NO:93, and a second expression vector comprising the nucleotide sequence of SEQ ID NO:95; 11) a first expression vector comprising the nucleotide sequence of SEQ ID NO:93, and a second expression vector comprising the nucleotide sequence of SEQ ID NO:96; 12) a first expression vector comprising the nucleotide sequence of SEQ ID NO: 102, and a second expression vector comprising the nucleotide sequence of SEQ ID NO: 105; 13) a first expression vector comprising the nucleotide sequence of SEQ ID NO: 102, and a second expression vector comprising the nucleotide sequence of SEQ ID NO: 106; 14) a first expression vector comprising the nucleotide sequence of SEQ ID NO: 103, and a second expression vector comprising the nucleotide sequence of SEQ ID NO: 105; 15) a first expression vector comprising the nucleotide sequence of SEQ ID NO: 103, and a second expression vector comprising the nucleotide sequence of SEQ ID NO: 106; 16) a first expression vector comprising the nucleotide sequence of SEQ ID NO: 104 and a second expression vector comprising the nucleotide sequence of SEQ ID NO: 105; or 17) A first expression vector comprising the nucleotide sequence of SEQ ID NO: 104, and a second expression vector comprising the nucleotide sequence of SEQ ID NO: 106.

[0056] In another aspect, the present invention provides an expression vector comprising: (I) a first nucleic acid sequence comprising a nucleotide sequence selected from the group consisting of SEQ ID NOs: 4, 17, 30, 42, 55, 92, 93, 102, 103 and 104; and (II) a second nucleic acid sequence comprising a nucleotide sequence selected from the group consisting of SEQ ID NOs: 9, 22, 35, 47, 60, 94, 95, 96, 105 and 106.

[0057] In some embodiments, the expression vector comprises: 1) a first nucleic acid sequence comprising the nucleotide sequence of SEQ ID NO:4 and a second nucleic acid sequence comprising the nucleotide sequence of SEQ ID NO:9; 2) a first nucleic acid sequence comprising the nucleotide sequence of SEQ ID NO: 17 and a second nucleic acid sequence comprising the nucleotide sequence of SEQ ID NO: 22; 3) a first nucleic acid sequence comprising the nucleotide sequence of SEQ ID NO:30 and a second nucleic acid sequence comprising the nucleotide sequence of SEQ ID NO:35; 4) a first nucleic acid sequence comprising the nucleotide sequence of SEQ ID NO:42 and a second nucleic acid sequence comprising the nucleotide sequence of SEQ ID NO:47; 5) a first nucleic acid sequence comprising the nucleotide sequence of SEQ ID NO:55 and a second nucleic acid sequence comprising the nucleotide sequence of SEQ ID NO:60; 6) a first nucleic acid sequence comprising the nucleotide sequence of SEQ ID NO: 92 and a second nucleic acid sequence comprising the nucleotide sequence of SEQ ID NO: 94; 7) a first nucleic acid sequence comprising the nucleotide sequence of SEQ ID NO: 92 and a second nucleic acid sequence comprising the nucleotide sequence of SEQ ID NO: 95; 8) a first nucleic acid sequence comprising the nucleotide sequence of SEQ ID NO: 92 and a second nucleic acid sequence comprising the nucleotide sequence of SEQ ID NO: 96; 9) a first nucleic acid sequence comprising the nucleotide sequence of SEQ ID NO:93 and a second nucleic acid sequence comprising the nucleotide sequence of SEQ ID NO:94; 10) a first nucleic acid sequence comprising the nucleotide sequence of SEQ ID NO: 93 and a second nucleic acid sequence comprising the nucleotide sequence of SEQ ID NO: 95; 11) a first nucleic acid sequence comprising the nucleotide sequence of SEQ ID NO:93 and a second nucleic acid sequence comprising the nucleotide sequence of SEQ ID NO:96; 12) a first nucleic acid sequence comprising the nucleotide sequence of SEQ ID NO: 102 and a second nucleic acid sequence comprising the nucleotide sequence of SEQ ID NO: 105; 13) a first nucleic acid sequence comprising the nucleotide sequence of SEQ ID NO: 102 and a second nucleic acid sequence comprising the nucleotide sequence of SEQ ID NO: 106; 14) a first nucleic acid sequence comprising the nucleotide sequence of SEQ ID NO: 103 and a second nucleic acid sequence comprising the nucleotide sequence of SEQ ID NO: 105; 15) a first nucleic acid sequence comprising the nucleotide sequence of SEQ ID NO: 103 and a second nucleic acid sequence comprising the nucleotide sequence of SEQ ID NO: 106; 16) a first nucleic acid sequence comprising the nucleotide sequence of SEQ ID NO: 104 and a second nucleic acid sequence comprising the nucleotide sequence of SEQ ID NO: 105; 17) A first nucleic acid sequence comprising the nucleotide sequence of SEQ ID NO:104 and a second nucleic acid sequence comprising the nucleotide sequence of SEQ ID NO:106.

[0058] In yet another aspect, the present invention provides a composition of isolated nucleic acid comprising: (I) a first nucleic acid comprising a nucleotide sequence selected from the group consisting of SEQ ID NOs: 97, 98, 107, 108, 109, 112, 113, 116 and 117; (II) a second nucleic acid comprising a nucleotide sequence selected from the group consisting of SEQ ID NOs: 99, 100, 101, 110, 111, 114 and 115.

[0059] In some embodiments, the composition of isolated nucleic acid comprises: 1) a first nucleic acid comprising SEQ ID NO:97 and a second nucleic acid comprising SEQ ID NO:99; 2) a first nucleic acid comprising SEQ ID NO: 97 and a second nucleic acid comprising SEQ ID NO: 100; 3) a first nucleic acid comprising SEQ ID NO:97 and a second nucleic acid comprising SEQ ID NO:101; 4) a first nucleic acid comprising SEQ ID NO:98 and a second nucleic acid comprising SEQ ID NO:99; 5) a first nucleic acid comprising SEQ ID NO: 98 and a second nucleic acid comprising SEQ ID NO: 100; 6) a first nucleic acid comprising SEQ ID NO:98 and a second nucleic acid comprising SEQ ID NO:101; 7) a first nucleic acid comprising SEQ ID NO: 107 and a second nucleic acid comprising SEQ ID NO: 110; 8) a first nucleic acid comprising SEQ ID NO: 107 and a second nucleic acid comprising SEQ ID NO: 111; 9) a first nucleic acid comprising SEQ ID NO: 108 and a second nucleic acid comprising SEQ ID NO: 110; 10) a first nucleic acid comprising SEQ ID NO: 108 and a second nucleic acid comprising SEQ ID NO: 111; 11) a first nucleic acid comprising SEQ ID NO: 109 and a second nucleic acid comprising SEQ ID NO: 110; 12) a first nucleic acid comprising SEQ ID NO: 109 and a second nucleic acid comprising SEQ ID NO: 111; 13) a first nucleic acid comprising SEQ ID NO:116 and a second nucleic acid comprising SEQ ID NO:110; 14) a first nucleic acid comprising SEQ ID NO:116 and a second nucleic acid comprising SEQ ID NO:111; 15) a first nucleic acid comprising SEQ ID NO: 117 and a second nucleic acid comprising SEQ ID NO: 110; 16) a first nucleic acid comprising SEQ ID NO: 117 and a second nucleic acid comprising SEQ ID NO: 111; 17) a first nucleic acid comprising SEQ ID NO: 112 and a second nucleic acid comprising SEQ ID NO: 114; 18) a first nucleic acid comprising SEQ ID NO: 112 and a second nucleic acid comprising SEQ ID NO: 115; 19) a first nucleic acid comprising SEQ ID NO: 113 and a second nucleic acid comprising SEQ ID NO: 114; or 20) A first nucleic acid comprising SEQ ID NO: 113 and a second nucleic acid comprising SEQ ID NO: 115.

[0060] In one aspect, the present invention provides an expression vector composition comprising: (I) a first expression vector comprising a nucleotide sequence selected from the group consisting of SEQ ID NOs: 97, 98, 107, 108, 109, 112, 113, 116 and 117; and (II) A second expression vector comprising a nucleotide sequence selected from the group consisting of SEQ ID NOs: 99, 100, 101, 110, 111, 114 and 115.

[0061] In some embodiments, an expression vector composition is provided that includes: 1) a first expression vector comprising the nucleotide sequence of SEQ ID NO:97, and a second expression vector comprising the nucleotide sequence of SEQ ID NO:99; 2) a first expression vector comprising the nucleotide sequence of SEQ ID NO: 97, and a second expression vector comprising the nucleotide sequence of SEQ ID NO: 100; 3) a first expression vector comprising the nucleotide sequence of SEQ ID NO:97, and a second expression vector comprising the nucleotide sequence of SEQ ID NO:101; 4) a first expression vector comprising the nucleotide sequence of SEQ ID NO:98, and a second expression vector comprising the nucleotide sequence of SEQ ID NO:99; 5) a first expression vector comprising the nucleotide sequence of SEQ ID NO: 98, and a second expression vector comprising the nucleotide sequence of SEQ ID NO: 100; 6) a first expression vector comprising the nucleotide sequence of SEQ ID NO: 98, and a second expression vector comprising the nucleotide sequence of SEQ ID NO: 101; 7) a first expression vector comprising the nucleotide sequence of SEQ ID NO: 107, and a second expression vector comprising the nucleotide sequence of SEQ ID NO: 110; 8) a first expression vector comprising the nucleotide sequence of SEQ ID NO: 107, and a second expression vector comprising the nucleotide sequence of SEQ ID NO: 111; 9) a first expression vector comprising the nucleotide sequence of SEQ ID NO: 108, and a second expression vector comprising the nucleotide sequence of SEQ ID NO: 110; 10) a first expression vector comprising the nucleotide sequence of SEQ ID NO: 108, and a second expression vector comprising the nucleotide sequence of SEQ ID NO: 111; 11) a first expression vector comprising the nucleotide sequence of SEQ ID NO: 109, and a second expression vector comprising the nucleotide sequence of SEQ ID NO: 110; 12) a first expression vector comprising the nucleotide sequence of SEQ ID NO: 109, and a second expression vector comprising the nucleotide sequence of SEQ ID NO: 111; 13) a first expression vector comprising the nucleotide sequence of SEQ ID NO: 116, and a second expression vector comprising the nucleotide sequence of SEQ ID NO: 110; 14) a first expression vector comprising the nucleotide sequence of SEQ ID NO:116, and a second expression vector comprising the nucleotide sequence of SEQ ID NO:111; 15) a first expression vector comprising the nucleotide sequence of SEQ ID NO: 117, and a second expression vector comprising the nucleotide sequence of SEQ ID NO: 110; 16) a first expression vector comprising the nucleotide sequence of SEQ ID NO: 117, and a second expression vector comprising the nucleotide sequence of SEQ ID NO: 111; 17) a first expression vector comprising the nucleotide sequence of SEQ ID NO: 112, and a second expression vector comprising the nucleotide sequence of SEQ ID NO: 114; 18) a first expression vector comprising the nucleotide sequence of SEQ ID NO: 112, and a second expression vector comprising the nucleotide sequence of SEQ ID NO: 115; 19) a first expression vector comprising the nucleotide sequence of SEQ ID NO: 113, and a second expression vector comprising the nucleotide sequence of SEQ ID NO: 114; or 20) A first expression vector comprising the nucleotide sequence of SEQ ID NO:113, and a second expression vector comprising the nucleotide sequence of SEQ ID NO:115.

[0062] In another aspect, the present invention provides an expression vector comprising: (I) a first nucleic acid sequence comprising a nucleotide sequence selected from the group consisting of SEQ ID NOs: 97, 98, 107, 108, 109, 112, 113, 116 and 117; and (II) a second nucleic acid sequence comprising a nucleotide sequence selected from the group consisting of SEQ ID NOs: 99, 100, 101, 110, 111, 114 and 115.

[0063] In some embodiments, the expression vector comprises: 1) a first nucleic acid sequence comprising the nucleotide sequence of SEQ ID NO:97 and a second nucleic acid sequence comprising the nucleotide sequence of SEQ ID NO:99; 2) a first nucleic acid sequence comprising the nucleotide sequence of SEQ ID NO: 97 and a second nucleic acid sequence comprising the nucleotide sequence of SEQ ID NO: 100; 3) a first nucleic acid sequence comprising the nucleotide sequence of SEQ ID NO: 97 and a second nucleic acid sequence comprising the nucleotide sequence of SEQ ID NO: 101; 4) a first nucleic acid sequence comprising the nucleotide sequence of SEQ ID NO:98 and a second nucleic acid sequence comprising the nucleotide sequence of SEQ ID NO:99; 5) a first nucleic acid sequence comprising the nucleotide sequence of SEQ ID NO: 98 and a second nucleic acid sequence comprising the nucleotide sequence of SEQ ID NO: 100; 6) a first nucleic acid sequence comprising the nucleotide sequence of SEQ ID NO: 98 and a second nucleic acid sequence comprising the nucleotide sequence of SEQ ID NO: 101; 7) a first nucleic acid sequence comprising the nucleotide sequence of SEQ ID NO: 107 and a second nucleic acid sequence comprising the nucleotide sequence of SEQ ID NO: 110; 8) a first nucleic acid sequence comprising the nucleotide sequence of SEQ ID NO: 107 and a second nucleic acid sequence comprising the nucleotide sequence of SEQ ID NO: 111; 9) a first nucleic acid sequence comprising the nucleotide sequence of SEQ ID NO: 108 and a second nucleic acid sequence comprising the nucleotide sequence of SEQ ID NO: 110; 10) a first nucleic acid sequence comprising the nucleotide sequence of SEQ ID NO: 108 and a second nucleic acid sequence comprising the nucleotide sequence of SEQ ID NO: 111; 11) a first nucleic acid sequence comprising the nucleotide sequence of SEQ ID NO: 109 and a second nucleic acid sequence comprising the nucleotide sequence of SEQ ID NO: 110; 12) a first nucleic acid sequence comprising the nucleotide sequence of SEQ ID NO: 109 and a second nucleic acid sequence comprising the nucleotide sequence of SEQ ID NO: 111; 13) a first nucleic acid sequence comprising the nucleotide sequence of SEQ ID NO: 116 and a second nucleic acid sequence comprising the nucleotide sequence of SEQ ID NO: 110; 14) a first nucleic acid sequence comprising the nucleotide sequence of SEQ ID NO: 116 and a second nucleic acid sequence comprising the nucleotide sequence of SEQ ID NO: 111; 15) a first nucleic acid sequence comprising the nucleotide sequence of SEQ ID NO: 117 and a second nucleic acid sequence comprising the nucleotide sequence of SEQ ID NO: 110; 16) a first nucleic acid sequence comprising the nucleotide sequence of SEQ ID NO: 117 and a second nucleic acid sequence comprising the nucleotide sequence of SEQ ID NO: 111; 17) a first nucleic acid sequence comprising the nucleotide sequence of SEQ ID NO: 112 and a second nucleic acid sequence comprising the nucleotide sequence of SEQ ID NO: 114; 18) a first nucleic acid sequence comprising the nucleotide sequence of SEQ ID NO: 112 and a second nucleic acid sequence comprising the nucleotide sequence of SEQ ID NO: 115; 19) a first nucleic acid sequence comprising the nucleotide sequence of SEQ ID NO: 113 and a second nucleic acid sequence comprising the nucleotide sequence of SEQ ID NO: 114; or 20) A first nucleic acid sequence comprising the nucleotide sequence of SEQ ID NO:113 and a second nucleic acid sequence comprising the nucleotide sequence of SEQ ID NO:115.

[0064] In yet another aspect, the invention provides a cell comprising any one of the expression vector compositions.

[0065] In certain aspects, the invention provides a method of preparing an isolated antibody or antigen-binding fragment thereof comprising expressing the isolated antibody or antigen-binding fragment thereof in a cell and isolating the isolated antibody or antigen-binding fragment thereof from the cell.

[0066] In another aspect, the invention provides a pharmaceutical composition comprising the isolated antibody or antigen-binding fragment thereof and a pharma- ceutically acceptable excipient.

[0067] In yet another aspect, the invention provides a kit comprising the isolated antibody or antigen-binding fragment thereof.

[0068] In some aspects, the present invention provides a method of treating a tumor comprising administering a therapeutically effective amount of an isolated antibody or antigen-binding fragment thereof, or a pharmaceutical composition to a subject in need thereof. In some embodiments, the tumor is selected from a solid tumor or a hematological tumor. In some embodiments, the tumor is selected from bladder cancer, breast cancer, cervical cancer, ovarian cancer, testicular cancer, prostate cancer, testicular cancer, esophageal cancer, gastrointestinal cancer, pancreatic cancer, colorectal cancer, colon cancer, renal cancer, head and neck cancer, lung cancer (small cell lung cancer or non-small cell lung cancer), gastric cancer, bone cancer, liver cancer, thyroid cancer, skin cancer, central nervous system tumors, lymphoma, leukemia, myeloma, sarcoma, and virus-associated cancer.

[0069] In another aspect, the present invention provides the use of an isolated antibody or antigen-binding fragment thereof, or a pharmaceutical composition for the manufacture of a medicament for treating a tumor. In some embodiments, the tumor is selected from bladder cancer, breast cancer, cervical cancer, ovarian cancer, prostate cancer, testicular cancer, esophageal cancer, gastrointestinal cancer, pancreatic cancer, colorectal cancer, colon cancer, renal cancer, head and neck cancer, lung cancer (small cell lung cancer or non-small cell lung cancer), gastric cancer, bone cancer, liver cancer, thyroid cancer, skin cancer, central nervous system tumors, lymphoma, leukemia, myeloma, sarcoma, and virus-associated cancer.

[0070] In yet another aspect, the present invention provides an isolated antibody or antigen-binding fragment thereof, or a pharmaceutical composition for use in treating a tumor. In some embodiments, the tumor is selected from a solid tumor or a hematological tumor. In some embodiments, the cancer is selected from bladder cancer, breast cancer, cervical cancer, ovarian cancer, testicular cancer, prostate cancer, esophageal cancer, gastrointestinal cancer, pancreatic cancer, colorectal cancer, colon cancer, renal cancer, head and neck cancer, lung cancer (small cell lung cancer or non-small cell lung cancer), gastric cancer, bone cancer, liver cancer, thyroid cancer, skin cancer, central nervous system tumors, lymphoma, leukemia, myeloma, sarcoma, and virus-associated cancer.

[0071] Table 1. Antibody sequence listing of the present invention JPEG0007623706000001.jpg202170JPEG0007623706000002.jpg191170JPEG0007623706000003.jpg197170JPEG0007623706000004. jpg219170JPEG0007623706000005.jpg191170JPEG0007623706000006.jpg209170JPEG0007623706000007.jpg217170JPEG00076237 06000008.jpg200170JPEG0007623706000009.jpg179170JPEG0007623706000010.jpg204170JPEG0007623706000011.jpg205170JPE G0007623706000012.jpg199170JPEG0007623706000013.jpg158170JPEG0007623706000014.jpg161170JPEG0007623706000015.jpg 155170JPEG0007623706000016.jpg205170JPEG0007623706000017.jpg121170JPEG0007623706000018.jpg158170JPEG00076237060 00019.jpg158170JPEG0007623706000020.jpg162170JPEG0007623706000021.jpg154170JPEG0007623706000022.jpg155170JPEG00 07623706000023.jpg156170JPEG0007623706000024.jpg153170JPEG0007623706000025.jpg164170JPEG0007623706000026.jpg210170JPEG0007623706000027.jpg184170JPEG0007623706000028.jpg212170Note: Except for sequences specifically noted here, all amino acid numbers are based on the Kabat system, EU index (Kabat, EA, et al. (1991) Sequences of Proteins of Immunological Interest, Fifth Edition, USDepartment of Health and Human Services, NIH Publication No. 91-3242). aa: amino acid, nt: nucleotide. [Brief description of the drawings]

[0072] [Figure 1] FIG. 1 shows the binding assay of positive clones and soluble huCD73 protein. [Diagram 2] FIG. 2 shows the binding assay of positive clones and native CD73 protein. [Diagram 3] FIG. 3 shows blocking activity of soluble recombinant human CD73. [Figure 4] FIG. 4 shows an activity inhibition test using cells. [Diagram 5] FIG. 5 shows CD4+ T cell proliferation reversed by CD73 antibody. [Figure 6] FIG. 6 shows that CD73 enzyme activity in CD4+ T cells was blocked by antibody. [Figure 7] FIG. 7 shows antibody-reversed IFN-γ release from CD4+ T cells. [Figure 8] FIG. 8 shows CD73 antibody-mediated CD73 endocytosis. [Figure 9] FIG. 9 shows the affinity of the humanized and chimeric antibodies as detected by ELISA. [Figure 10] FIG. 10 shows the affinity of humanized and chimeric antibodies as detected by FAC. [Figure 11] FIG. 11 shows that 5' exonuclease activity on the cell surface was blocked by humanized antibodies. [Figure 12] FIG. 12 shows that 5′ ectonucleotidase activity of U87-MG cells was blocked by humanized antibodies. [Figure 13] FIG. 13 shows CD4+ T cell proliferation reversed by humanized CD73 antibody. [Figure 14]FIG. 14 shows that IFN-γ released from CD4+ T cells was reversed by humanized CD73 antibody. [Figure 15] FIG. 15A and FIG. 15B show the inhibitory effect of humanized antibodies on tumor 5′ exonuclease activity in a xenograft animal model. [Figure 16] Figure 16 shows the tumor suppressive effect of humanized antibodies against the A375 human melanoma xenograft model.

[0073] Described herein are isolated antibodies, particularly monoclonal antibodies, e.g., human monoclonal antibodies that specifically bind to CD73 and thereby reduce CD73 activity ("antagonist anti-CD73 antibodies"). In certain embodiments, the antibodies described herein are derived from specific heavy and light chain germline sequences and / or contain specific structural features, such as CDR regions that contain specific amino acid sequences. Provided herein are isolated antibodies, methods of preparing such antibodies. Also provided herein are methods of using the antibodies alone or in combination with other therapeutic agents (e.g., antibodies) and / or cancer therapies to reduce tumor growth. Thus, the anti-CD73 antibodies described herein can be used to treat a wide variety of therapeutic applications, including, for example, inhibiting tumor growth, inhibiting metastasis, and enhancing immune responses against tumors. <Definition>

[0074] In order that this description may be more readily understood, certain terms are first defined. Additional definitions are set forth throughout the detailed description.

[0075] As used herein, the term "cluster of differentiation 73" or "CD73" refers to an enzyme (nucleotidase) capable of converting extracellular nucleoside 5' monophosphates to nucleosides, i.e., an enzyme that converts adenosine monophosphate (AMP) to adenosine. CD73 is usually found as a dimer anchored to the cell membrane via a glycosylphosphatidylinositol (GPI) linkage, has ectoenzymatic activity, and plays a role in signal transduction. The main function of CD73 is to convert extracellular nucleotides (e.g., 5'AMP) to adenosine, a highly immunosuppressive molecule. Thus, ecto-5'-nucleotidase catalyzes the dephosphorylation of purine and pyrimidine ribo- and deoxyribonucleoside monophosphates to the corresponding nucleosides. CD73 has broad substrate specificity, but prefers purine-based ribonucleosides.

[0076] CD73 is also referred to as ecto-5' nuclease (ecto-5'NT, EC 3.1.3.5). The term "CD73" includes any variant or isoform of CD73 that is naturally expressed by cells. Thus, the antibodies described herein can cross-react with CD73 from species other than human (e.g., cynomolgus monkey CD73). Alternatively, the antibodies may be specific for human CD73 and may not show any cross-reactivity with other species. CD73 or any variants and isoforms thereof may be isolated from cells or tissues that naturally express them or may be recombinantly produced using techniques well known in the art and / or described herein.

[0077] Two isoforms of human CD73 have been identified, both sharing the same N- and C-terminal portions. Isoform 1 (Accession No. NP_002517.1; SEQ ID NO: 1) represents the longest protein, consisting of 574 amino acids and 9 exons. Isoform 2 (Accession No. NP_001191742.1) encodes a shorter protein of 524 amino acids that lacks amino acids 404-453. Isoform 2 lacks the alternating in-frame exons, resulting in a transcript with only 8 exons, but with identical N- and C-terminal sequences.

[0078] The cynomolgus monkey (cyno) CD73 protein sequence is provided as SEQ ID NO: 2. The terms cynomolgus and cyno both refer to the species Macaca fascicularis and are used interchangeably throughout the specification.

[0079] The term "antibody" as used herein may include whole antibodies and any antigen-binding fragments (i.e., "antigen-binding portions") or single chains thereof. In one embodiment, "antibody" refers to a glycoprotein or antigen-binding portion thereof comprising at least two heavy (H) chains and two light (L) chains interconnected by disulfide bonds. Each heavy chain consists of a heavy chain variable region (abbreviated herein as VH) and a heavy chain constant region. In some naturally occurring IgG, IgD and IgA antibodies, the heavy chain constant region consists of three domains, CH1, CH2 and CH3. In some naturally occurring antibodies, each light chain consists of a light chain variable region (abbreviated herein as VL) and a light chain constant region. The light chain constant region consists of one domain, CL. The VH and VL regions can be further subdivided into regions of hypervariability called complementarity determining regions (CDRs) and more conserved regions called framework regions (FRs), both in a mixed arrangement. Herein, the CDRs of the VH region are abbreviated as HCDRs. That is, the three CDRs of the VH region can be abbreviated as HCDR1, HCDR2, and HCDR3. The CDR of the VL region is abbreviated as LCDR. That is, the three CDRs of the VL region can be abbreviated as LCDR1, LCDR2, and LCDR3. Each VH and VL is composed of three CDRs and four FRs, which are arranged from the amino terminus to the carboxy terminus in the following order: FR1, CDR1, FR2, CDR2, FR3, CDR3, and FR4. The variable regions of the heavy and light chains contain binding domains that interact with antigens. The constant region of the antibody can mediate the binding of the immunoglobulin to host tissues or factors, including various cells of the immune system (e.g., effector cells) and the first component (C1q) of the classical complement system.

[0080] The heavy chain of an antibody may or may not include a terminal lysine (K) or a terminal glycine and lysine (GK). Thus, any of the heavy chain sequences and heavy chain constant region sequences provided herein can end in either GK or G, or can lack the K or GK, regardless of what the last amino acid of the sequence is provided, because the terminal lysine, and sometimes the glycine and lysine, are cleaved during expression of the antibody.

[0081] Typically, antibodies are -7 From 10 -11 The dissociation constant (K D ) specifically binds to its cognate antigen with high affinity as reflected by approximately 10 -6 K is bigger than M D As used herein, an antibody that "specifically binds" to an antigen binds to the antigen with high affinity (which is greater than or equal to 10 -7 M or less, preferably 10 -8 M or less, and even more preferably 5×10 -9 M or less, and most preferably 10 -8 M to 10 -10 K between M and below D "Substantially identical" refers to an antibody that binds to a given antigen with high affinity (meaning that it has at least 80%, at least 90%, at least 95%, at least 97%, or at least 99% or more sequence identity to the sequence of the given antigen) but does not bind to unrelated antigens with high affinity. An antigen is "substantially identical" to a given antigen if it exhibits a high degree of sequence identity with the given antigen, for example, if it exhibits at least 80%, at least 90%, at least 95%, at least 97%, or at least 99% or more sequence identity to the sequence of the given antigen. By way of example, an antibody that specifically binds to human CD73 may also cross-react with CD73 from some non-human primate species (e.g., cynomolgus monkeys), but may not cross-react with CD73 from other species or antigens other than CD73.

[0082] Immunoglobulins may be from any of the commonly known isotypes, including, but not limited to, IgA, secretory IgA, IgG, and IgM. The IgG isotype is divided into subclasses in certain species: IgG1, IgG2, IgG3, and IgG4 in humans, and IgG1, IgG2a, IgG2b, and IgG3 in mice. In certain embodiments, the anti-CD73 antibodies described herein are of the human IgG1 or IgG2 subtype. Immunoglobulins, such as human IgG1, exist in several allotypes, which differ from each other by at most a small number of amino acids. An "antibody" may include, by way of example, both naturally occurring and non-naturally occurring antibodies; monoclonal and polyclonal antibodies; chimeric and humanized antibodies; human and non-human antibodies; totally synthetic antibodies; and single chain antibodies.

[0083] As used herein, the term "antigen-binding portion" of an antibody refers to one or more fragments of an antibody that retain the ability to specifically bind to an antigen (e.g., human CD73). It has been shown that the antigen-binding function of an antibody can be performed by fragments of a full-length antibody. Binding fragments encompassed within the term "antigen-binding portion" of an antibody, such as an anti-CD73 antibody described herein, include (i) a Fab fragment, which is a monovalent fragment consisting of the VL, VH, CL and CH1 domains, (ii) an F(ab') fragment, which is a bivalent fragment comprising two Fab fragments linked by a disulfide bridge at the hinge region. 2(iii) Fd fragments consisting of the VH and CH1 domains, (iv) Fv fragments consisting of the VL and VH domains of a single arm of an antibody, (v) dAb fragments consisting of the VH domain (Ward et al., (1989) Nature 341:544-546), and (vi) isolated complementarity determining regions (CDRs) or (vii) combinations of two or more isolated CDRs that can optionally be linked by a synthetic linker. Furthermore, although the two domains of the Fv fragment, VL and VH, are encoded by different genes, they can be linked using recombinant methods by a synthetic linker that allows the VL and VH domains to be made into a single protein linkage that pairs to form a monovalent molecule known as a single chain Fv (scFv). See, e.g., Bird et al. (1988) Science 242:423-426; and Huston et al. (1988) Proc.Natl.Acad.Sci.USA 85:5879-5883). Such single chain antibodies are also intended to be encompassed within the term "antigen-binding portion" of an antibody. These and other possible constructs are described in Chan & Carter (2010) Nat.Rev.Immunol.10:301. These antibody fragments are obtained using conventional techniques known to those of skill in the art, and the fragments are screened for utility in the same manner as intact antibodies. Antigen-binding portions can be produced by recombinant DNA techniques, or by enzymatic or chemical cleavage of intact immunoglobulins.

[0084] The term "conservatively modified amino acid sequence" refers to amino acid modifications that do not significantly affect or change the binding characteristics of the antibody containing the amino acid sequence, including amino acid substitutions, additions and deletions. Modifications can be introduced into the antibody of the present invention by standard techniques such as site-directed mutagenesis and PCR-mediated mutagenesis. Conservative amino acid substitutions are those in which an amino acid residue is replaced with an amino acid residue having a similar side chain. Families of amino acid residues having similar side chains have been defined in the art. These families include amino acids with basic side chains (e.g., lysine, arginine, histidine), acidic side chains (e.g., aspartic acid, glutamic acid), uncharged polar side chains (e.g., glycine, asparagine, glutamine, serine, threonine, tyrosine, cysteine, tryptophan), nonpolar side chains (e.g., alanine, valine, leucine, isoleucine, proline, phenylalanine, methionine), beta-branched side chains (e.g., threonine, valine, isoleucine) and aromatic side chains (e.g., tyrosine, phenylalanine, tryptophan, histidine). Thus, one or more amino acid residues in the CDR regions of the antibodies of the invention can be replaced with other amino acid residues from the same side chain family, and the modified antibodies can be tested for retained function using the functional assays described herein. Preferably, there are no more than one or two conservative modifications.

[0085] A "bispecific" or "bifunctional antibody" is an artificial hybrid antibody having two different heavy / light chain pairs, resulting in two antigen-binding sites with specificities for different antigens. Bispecific antibodies can be produced by a variety of methods, including fusion of hybridomas or linking of Fab' fragments. See, e.g., Songsivilai & Lachmann, Clin.Exp.Immunol.79:315-321 (1990); Kostelny et al., J. Immunol.148, 1547-1553 (1992).

[0086] The term "monoclonal antibody" as used herein refers to an antibody that exhibits a single binding specificity and affinity to a specific epitope, or a composition of antibodies in which all of the antibodies exhibit a single binding specificity and affinity to a specific epitope. Typically, such monoclonal antibodies will be derived from a single antibody encoding cell or nucleic acid and propagated without intentionally introducing any sequence changes. Thus, the term "human monoclonal antibody" refers to a monoclonal antibody that has variable and any constant regions derived from human germline immunoglobulin sequences. In certain embodiments, human monoclonal antibodies are produced by hybridomas obtained by fusing, for example, B cells derived from transgenic or chromosomal non-human animals (e.g., transgenic mice with genomes containing human heavy and light chain transgenes) with immortalized cells.

[0087] The term "recombinant human antibody" as used herein includes all human antibodies that are prepared, expressed, produced or isolated by recombinant means, such as (a) antibodies isolated from animals (e.g., mice) that are transgenic or transchromosomal for human immunoglobulin genes or hybridomas prepared therefrom, (b) antibodies isolated from host cells, e.g., transfectomas, that have been transformed to express the antibody, (c) antibodies isolated from recombinant, combinatorial human antibody libraries, and (d) antibodies prepared, expressed, produced or isolated by any other means, including splicing of human immunoglobulin gene sequences to other DNA sequences. Such recombinant human antibodies utilize specific human germline immunoglobulin sequences and contain variable and constant regions encoded by germline genes, but include subsequent rearrangements and mutations that occur, for example, during antibody maturation. As is known in the art (see, e.g., Lonberg (2005) Nature Biotech. 23(9):11171125), the variable region comprises antigen-binding domains encoded by different genes that rearrange to form antibodies specific to exogenous antigens. In addition to rearrangement, the variable region can be further modified by multiple single amino acid changes (called somatic mutation or hypermutation) to increase the affinity of the antibody cell for the foreign antigen. The constant region can further change in response to the antigen (i.e., isotype switching). Thus, the rearranged and somatically mutated nucleic acid sequences that encode light and heavy immunoglobulin polypeptides in response to an antigen may not be identical to the original germline sequences, but instead may be substantially identical or similar (i.e., have at least 80% identity).

[0088] "Human" antibody (HuMAb) refers to an antibody having variable regions in which both the framework and CDR regions are derived from human germline immunoglobulin sequences. Furthermore, if the antibody contains a constant region, the constant region is also derived from a human germline immunoglobulin sequence. The antibodies described herein may contain amino acid residues not encoded by human germline immunoglobulin sequences (e.g., mutations introduced by random or site-specific mutagenesis in vitro or by somatic mutation in vivo). However, the term "human antibody" as used herein is not intended to include antibodies in which CDR sequences derived from the germline of another mammalian species, such as a mouse, have been grafted onto human framework sequences. The terms "human" antibody and "fully human" antibody are used interchangeably.

[0089] "Humanized" antibody refers to an antibody in which some, most or all of the amino acids outside the CDR domain of a non-human antibody are replaced with the corresponding amino acids from a human immunoglobulin. In one embodiment of a humanized form of an antibody, some, most or all of the amino acids outside the CDR domain are replaced with amino acids from a human immunoglobulin, while some, most or all of the amino acids within one or more CDR regions remain unchanged. Small additions, deletions, insertions, substitutions or modifications of amino acids are permissible as long as they do not interfere with the ability of the antibody to bind to a specific antigen. A "humanized" antibody retains antigen specificity similar to that of the original antibody.

[0090] A "chimeric antibody" refers to an antibody in which the variable region is derived from one species and the constant region is derived from another species, e.g., the variable region is derived from a murine antibody and the constant region is derived from a human antibody.

[0091] "Modified heavy chain constant region" means a heavy chain constant region comprising constant domains CH1, hinge, CH2, and CH3, where one or more of the constant domains are from a different isotype (e.g., IgG1, IgG2, IgG3, IgG4). In some embodiments, the modified constant region comprises a human IgG2 hinge fused to a human IgG2 CH1 domain and a human IgG1 CH2 domain and a human IgG1 CH3 domain. In certain embodiments, such modified constant regions also contain amino acid modifications within one or more domains relative to the wild-type amino acid sequence.

[0092] As used herein, "isotype" refers to the antibody class (e.g., IgG1, IgG2, IgG3, IgG4, IgM, IgA1, IgA2, IgD, and IgE antibodies) encoded by heavy chain constant region genes.

[0093] "Allotype" refers to naturally occurring variants within a specific isotype family that differ in some amino acids (see, e.g., Jefferis et al. (2009) mAb1:1). The antibodies described herein can be of any allotype.

[0094] Unless otherwise specified herein, all amino acid numbers are according to the Kabat system, EU index (Kabat, EA, et al. (1991) Sequences of Proteins of Immunological Interest, Fifth Edition, US Department of Health and Human Services, NIH Publication No. 91-3242).

[0095] The terms "an antibody that recognizes an antigen" and "an antibody specific for an antigen" are used interchangeably herein with the term "an antibody that specifically binds to an antigen."

[0096] As used herein, the term "isolated antibody" is intended to refer to an antibody that is substantially free of other antibodies having different antigenic specificities (e.g., an isolated antibody that specifically binds to CD73 is substantially free of antibodies that specifically bind to antigens other than CD73). However, an isolated antibody that specifically binds to an epitope of CD73 may have cross-reactivity with other CD73 proteins from various species.

[0097] As used herein, an antibody that "inhibits CD73" refers to an antibody that inhibits the biological and / or enzymatic functions of CD73. These functions include, for example, the ability of the antibody to inhibit CD73 enzymatic activity, e.g., CD73-regulated production of adenosine or reduction in cAMP production.

[0098] As used herein, an "internalizing" antibody refers to an antibody that crosses the cell membrane upon binding to a cell surface antigen. Internalization includes antibody-mediated receptor, e.g., CD73, internalization. In some embodiments, the antibody has a T equal to about 10 minutes or less. 1 / 2 It is rapidly "internalized" into cells expressing CD73.

[0099] "Effector function" refers to the interaction of an antibody Fc region with an Fc receptor or ligand, or a biochemical event resulting therefrom. Exemplary "effector functions" include C1q binding, complement-dependent cytotoxicity (CDC), Fc receptor binding, FcγR-mediated effector functions such as ADCC and antibody-dependent cell-mediated phagocytosis (ADCP), and downregulation of cell surface receptors (e.g., B cell receptor; BCR). Such effector functions generally require the Fc region to bind to a binding domain (e.g., an antibody variable domain).

[0100] An "Fc receptor" or "FcR" is a receptor that binds to the Fc region of an immunoglobulin. FcRs that bind IgG antibodies include receptors of the FcγR family, including allelic variants and alternatively spliced ​​forms of these receptors. The FcγR family consists of three activating receptors (FcγRI, FcγRIII, FcγRIV in mice; FcγRIA, FcγRIIA, FcγRIIIA in humans) and one inhibitory receptor (FcγRIIB). The various properties of human FcγRs are summarized in Table A. The majority of innate effector cell types co-express one or more activating FcγRs and an inhibitory FcγRIIB, whereas natural killer (NK) cells selectively express one activating Fc receptor (FcγRIII in mice and FcγRIIIA in humans) but do not express inhibitory FcγRIIB in mice and humans. Human IgG1 binds to most human Fc receptors, and the types of activating Fc receptors it binds to are thought to be equivalent to those of mouse IgG2a.

[0101] Table A. Characteristics of human FcγR JPEG0007623706000029.jpg123170

[0102] "Hinge", "hinge domain" or "hinge region" or "antibody hinge region" refers to the domain of the heavy chain constant region that connects the CH1 domain to the CH2 domain and includes the upper, middle, and lower parts of the hinge (Roux et al. J. Immunol. 1998 161:4083). The hinge provides a variable level of flexibility between the binding and effector regions of the antibody and also provides a site for intermolecular disulfide bonds between the two heavy chain constant regions. The term "hinge" includes wild-type hinges, as well as variants thereof (e.g., non-naturally occurring hinges or modified hinges). For example, the term "IgG2 hinge" includes wild-type IgG2 hinges and variants with 1, 2, 3, 4, 5, 1-3, 1-5, 3-5, and / or at most 5, 4, 3, 2, or 1 mutations, such as substitutions, deletions, or additions.

[0103] The term "CH1 domain" refers to the heavy chain constant region that connects the variable domain to the hinge in the heavy chain constant domain. The term "CH1 domain" includes wild-type CH1 domains, as well as variants thereof (e.g., non-naturally occurring CH1 domains or modified CH1 domains). For example, the term "CH1 domain" includes wild-type CH1 domains and variants thereof that have 1, 2, 3, 4, 5, 1-3, 1-5, 3-5 and / or at most 5, 4, 3, 2, or 1 mutations, such as substitutions, deletions, or additions.

[0104] Exemplary CH1 domains include CH1 domains with mutations that alter the biological activity of the antibody, such as ADCC, CDC or half-life. Modifications of the CH1 domain that affect the biological activity of the antibody are provided herein.

[0105] The term "CH2 domain" refers to the heavy chain constant region that connects the hinge in the heavy chain constant domain to the CH3 domain. The term "CH2 domain" includes wild-type CH2 domains, as well as variants thereof (e.g., non-naturally occurring or modified CH2 domains). For example, the term "CH2 domain" includes wild-type CH2 domains and variants thereof that have 1, 2, 3, 4, 5, 1-3, 1-5, 3-5 and / or at most 5, 4, 3, 2, or 1 mutations, such as substitutions, deletions, or additions. Exemplary CH2 domains include CH2 domains that have mutations that alter the biological activity of the antibody, such as ADCC, CDC, or half-life.

[0106] The term "CH3 domain" refers to the heavy chain constant region that is C-terminal to the CH2 domain in the heavy chain constant domain. The term "CH3 domain" includes wild-type CH3 domains, as well as variants thereof (e.g., non-naturally occurring CH3 domains or modified CH3 domains). For example, the term "CH3 domain" includes wild-type CH3 domains and variants thereof with 1, 2, 3, 4, 5, 1-3, 1-5, 3-5 and / or at most 5, 4, 3, 2, or 1 mutations, such as substitutions, deletions, or additions. Exemplary CH3 domains include CH3 domains with mutations that alter the biological activity of the antibody, such as ADCC, CDC, or half-life. Modifications of CH3 domains that affect the biological activity of the antibody are provided herein.

[0107] "CL domain" refers to a constant domain of a light chain. The term "CL domain" includes the wild-type CL domain and variants thereof.

[0108] A "native sequence Fc region" or "native sequence Fc" comprises an amino acid sequence identical to the amino acid sequence of an Fc region found in nature. Native sequence human Fc regions include native sequence human IgG1 Fc regions; native sequence human IgG2 Fc regions; native sequence human IgG3 Fc regions; and native sequence human IgG4 Fc regions, as well as naturally occurring variants thereof. Native sequence Fc includes the various allotypes of Fc (see, e.g., Jefferis et al. (2009) mAb1:1).

[0109] The term "epitope" or "antigenic determinant" refers to a site on an antigen (e.g., CD73) to which an immunoglobulin or antibody specifically binds. Epitopes of protein antigens can be formed from both contiguous amino acids (usually linear epitopes) and non-contiguous amino acids juxtaposed by tertiary folding of a protein (usually conformational epitopes). Epitopes formed from contiguous amino acids are typically, but not always, retained when exposed to denaturing solvents, whereas epitopes formed by tertiary folding are typically lost when treated with denaturing solvents. Epitopes typically include at least 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14 or 15 amino acids in a unique spatial conformation. Methods for determining what epitope is bound by a given antibody (i.e., epitope mapping) are well known in the art and include, for example, immunoblotting and immunoprecipitation analysis, in which overlapping or adjacent peptides (e.g., from CD73) are tested for reactivity with a given antibody (e.g., an anti-CD73 antibody). Methods for determining the spatial structure of an epitope include techniques in the art and described herein, such as X-ray crystallography, 2-dimensional nuclear magnetic resonance, and HDX-MS (see, for example, Epitope Mapping Protocols in Methods in Molecular Biology, Vol. 66, GE Morris, Ed. (1996)).

[0110] The term "epitope mapping" refers to the process of identifying the molecular determinants on an antigen that are involved in antibody-antigen recognition.

[0111] The term "binds to the same epitope" in reference to two or more antibodies means that the antibodies bind to the same segment of amino acid residues as determined by a given method. Techniques for determining whether an antibody binds to the "same epitope on CD73" of the antibodies described herein include, for example, X-ray analysis of crystals of antigen:antibody complexes, which provide atomic resolution of the epitope, and epitope mapping methods such as hydrogen / deuterium exchange mass spectrometry (HDX-MS). In other methods that monitor antibody binding to antigen fragments (e.g., proteolytic fragments) or mutant variants of the antigen, loss of binding due to modification of amino acid residues in the antigen sequence is often considered indicative of epitope components (e.g., alanine scanning mutagenesis-Cunningham & Wells (1985) Science 244: 1081). In addition, computational combinatorial methods for epitope mapping can also be used. These methods rely on the ability of the antibody of interest to affinity isolate specific short peptides from combinatorial phage display peptide libraries.

[0112] An antibody that "competes with another antibody for binding to a target" means an antibody that inhibits (partially or completely inhibits) the binding of another antibody to a target. Whether two antibodies compete with each other for binding to a target, i.e., whether and to what extent one antibody inhibits the binding of another antibody to a target, can be determined using known competition experiments such as those described in the Examples. In certain embodiments, an antibody competes with another antibody and inhibits at least 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90% or 100% of the binding. The degree of inhibition or competition can vary depending on which antibody is the "blocking antibody" (i.e., the cold antibody that is first incubated with the target). Competitive assays can be performed, for example, as described in Ed Harlow and David Lane, Cold Spring Harb Pro toe; 2006; doi: 10.1101 / pdb.prot4277 or "Using Antibodies" Chapter 11 by Ed Harlow and David Lane, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY, USA 1999. Competing antibodies may bind to the same epitope, overlapping epitopes, or adjacent epitopes (e.g., as evidenced by steric hindrance).

[0113] Other competitive binding assays include solid-phase direct or indirect radioimmunoassays (RIA), solid-phase direct or indirect enzyme immunoassays (see Stahli et al., Methods in Enzymology 9:242 (1983)); solid-phase direct biotin-avidin EIA (see Kirkland et al., J. Immunol. 137:3614 (1986)); solid-phase direct labeled sandwich assay (see Harlow and Lane, Antibodies: A Laboratory Manual, Cold Spring Harbor Press (1988)); solid-phase direct labeled RIA using I-125 labeling (see Morel et al., Mol. Immunol. 25(1):7 (1988)); solid-phase direct biotin-avidin EIA (Cheung et al., Virology 176:546 (1990)); and direct labeled RIA (Moldenhauer et al., Scand. J. Immunol 32:77 (1990)).

[0114] As used herein, the terms "specific binding," "selective binding," "selective binding," and "specific binding" refer to an antibody that binds to a predefined epitope on an antigen but not to other antigens. Typically, an antibody binds to a predefined antigen, e.g., recombinant human CD73, as an analyte and an antibody as a ligand, at a binding affinity of approximately 10, as measured by, e.g., surface plasmon resonance (SPR) technology in a BIACORE® 2000 surface plasmon resonance instrument, or by Scatchard analysis of the binding of the antibody to antigen-positive cells. -7 M, for example, about 10 -8 M or 10 -9 M or 10 -10 M or even lower, and (ii) bind to a given antigen with an affinity that is at least two-fold greater than the affinity of binding to a nonspecific antigen other than the given antigen or a closely related antigen (e.g., BSA, casein). Thus, unless otherwise indicated, an antibody that "specifically binds to human CD73" is one that is at least 10 -7Antibodies that bind to soluble or cell-bound human CD73 with a KD of less than or equal to approximately 10 -8 M, 10 -9 M, or 10 -10 An antibody that "cross-reacts with cynomolgus monkey CD73" refers to an antibody with a 10 -8 M, 10 -9 M, or 10 -10 M or less, etc., 10 -7 It refers to an antibody that binds to cynomolgus monkey CD73 with a KD of less than or equal to M. In certain embodiments, antibodies that do not cross-react with CD73 from non-human species exhibit substantially undetectable binding to these proteins in routine binding assays.

[0115] As used herein, the term "Kassoc" or "Ka" is intended to refer to the association rate constant of a specific antibody-antigen interaction, while the term "Kdis" or "Kd" is intended to refer to the dissociation rate constant of a specific antibody-antigen interaction. D " as used herein is intended to refer to the equilibrium dissociation constant obtained from the ratio of Kd to Ka (i.e., Kd / Ka) and expressed as a molar concentration (M). The K D The K value can be measured using methods well established in the art. D A preferred method for determining is by analysis using surface plasmon resonance, preferably using a biosensor system such as a Biacore® surface plasmon resonance system or flow cytometry and Scatchard.

[0116] The term "EC50" in the context of in vitro or in vivo assays using an antibody or antigen-binding fragment thereof means the concentration of an antibody or antigen-binding portion thereof that induces a response that is 50% of the maximal response, i.e., halfway between the maximal response and baseline.

[0117] The "rate of internalization" of an antibody or receptor, e.g., of CD73, mediated by, e.g., an anti-CD73 antibody, can be determined, e.g., as shown in the Examples, by measuring the T 1 / 2 The rate of internalization of an anti-CD73 antibody can be enhanced by at least 10%, 30%, 50%, 75%, 2 times, 3 times, 5 times or more, such that by altering the heavy chain constant region of the antibody to one that contains an engineered heavy chain constant region, e.g., an IgG2 hinge and an IgG2 CH1 domain, the rate of internalization of the anti-CD73 antibody can be enhanced by at least 10%, 30%, 50%, 75%, 2 times, 3 times, 5 times or more, such that ... 1 / 2 can be decreased by at least 10%, 30%, 50%, 75%, 2 times, 3 times, 5 times or more. For example, T 1 / 2 Instead of having a T 1 / 2 to 5 min (i.e., the rate of internalization increases by a factor of two or T 1 / 2 (The number of units is reduced by two.) 1 / 2 " is defined as the "time at which half of maximum internalization is achieved" measured from the time the antibody is added to the cells. The maximum level of internalization is the level of internalization at the plateau of a graph showing internalization plotted against antibody concentration. The modified heavy chain constant region may increase the maximum level of antibody internalization by at least 10%, 30%, 50%, 75%, 2-fold, 3-fold, 5-fold or more. Another way to compare the internalization effect of different antibodies, e.g., the same antibody with and without a modified heavy chain constant region, is to compare the level of internalization at a certain antibody concentration (e.g., 100 nM) or a given time (e.g., 2 minutes, 5 minutes, 10 minutes, 30 minutes). Comparing the level of internalization can also be done by comparing the EC50 level of internalization.

[0118] The term "naturally occurring" as used herein refers to the fact that the subject is found in nature. For example, a polypeptide or polynucleotide sequence that is present in an organism (including a virus) that exists in nature and has not been intentionally modified by humans in a laboratory is naturally occurring.

[0119] A "polypeptide" refers to a chain that contains at least two consecutive linked amino acid residues, with no upper limit on the length of the chain. One or more amino acid residues in a protein may contain modifications, such as, but not limited to, glycosylation, phosphorylation, or disulfide bonds. A "protein" may include one or more polypeptides.

[0120] The term "nucleic acid molecule" as used herein is intended to include DNA molecules and RNA molecules. The nucleic acid molecule may be single-stranded or double-stranded, and may be cDNA. Also provided are "conservative sequence modifications" of the sequences shown in the SEQ ID NOs described herein, i.e., nucleotide and amino acid sequence modifications that do not prevent the antibody encoded by the nucleotide sequence containing the amino acid sequence from binding to the antigen. Such conservative sequence modifications include conservative nucleotide and amino acid substitutions, as well as nucleotide and amino acid additions and deletions. Modifications can be introduced into the SEQ ID NOs described herein by standard techniques known in the art, such as, for example, site-directed mutagenesis and PCR-mediated mutagenesis. Conservative sequence modifications include conservative amino acid substitutions, in which an amino acid residue is replaced with an amino acid residue having a similar side chain. Families of amino acid residues having similar side chains have been defined in the art. These families include amino acids with basic side chains (e.g., lysine, arginine, histidine), acidic side chains (e.g., aspartic acid, glutamic acid), uncharged polar side chains (e.g., glycine, asparagine, glutamine, serine, threonine, tyrosine, cysteine, tryptophan), nonpolar side chains (e.g., alanine, valine, leucine, isoleucine, proline, phenylalanine, methionine), beta-branched side chains (e.g., threonine, valine, isoleucine) and aromatic side chains (e.g., tyrosine, phenylalanine, tryptophan, histidine). Thus, a predicted non-essential amino acid residue in an anti-CD73 antibody is preferably replaced with another amino acid residue from the same side chain family. Methods for identifying conservative nucleotide and amino acid substitutions that do not eliminate antigen binding are well known in the art (see, e.g., Brummell et al., Biochem. 32: 1180-1187 (1993); Kobayashi et al. Protein Eng. 12(10):879-884 (1999); and Burks et al. Proc. Natl. Acad. Sci. USA 94:412-417 (1997)).Alternatively, in another embodiment, mutations can be introduced randomly along all or part of the anti-CD73 antibody coding sequence, such as by saturation mutagenesis, and the resulting modified anti-CD73 antibodies can be screened for improved binding activity.

[0121] With respect to nucleic acids, the term "substantial identity" indicates that two nucleic acids, or designated sequences thereof, when optimally aligned and compared, are identical in at least about 80% of the nucleotides, usually at least about 90%-95% of the nucleotides, and more preferably at least about 98%-99.5% of the nucleotides, with appropriate nucleotide insertions or deletions. Alternatively, substantial identity exists when the segments will hybridize under selective hybridization conditions to the complement of the strand.

[0122] With respect to polypeptides, the term "substantial identity" indicates that two polypeptides, or designated sequences thereof, when optimally aligned and compared, are identical in at least about 80% of the amino acids, usually at least about 90%-95%, and more preferably at least about 98%-99.5% of the amino acids, with appropriate amino acid insertions or deletions.

[0123] The percent identity between two sequences is a function of the number of identical positions shared by the sequences when they are optimally aligned (i.e., % identity = number of identical positions / total number of positions x 100). Optimal alignment is determined by considering the number of gaps and the length of each gap that needs to be introduced for optimal alignment of the two sequences. As described in the non-limiting examples below, the comparison of sequences and determination of percent identity between two sequences can be performed using a mathematical algorithm.

[0124] The percent identity between two nucleotide sequences can be determined using the GAP program in the GCG software package (available at http: / / www.gcg.com) using NWSgapdna, a CMP matrix and gap weights of 40, 50, 60, 70, or 80, and length weights of 1, 2, 3, 4, 5, or 6. The percent identity between two nucleotide or amino acid sequences can also be determined using the algorithm of E. Meyers and W. Miller (CAB, 4: 11-17 (1989)) as incorporated into the ALIGN program (version 2.0), using a PAM120 weight residue table, a gap length penalty of 12, and a gap penalty of 4. Furthermore, the percent identity between two amino acid sequences can be determined using the algorithm of Needleman and Wunsch (J. Mol. Biol. (48):444-453(1970)) as incorporated into the GAP program in the GCG software package (available at http: / / www.gcg.com), using either a Blossum 62 matrix or a PAM250 matrix, and a gap weight of 16, 14, 12, 10, 8, 6, or 4, and a length weight of 1, 2, 3, 4, 5, or 6.

[0125] The nucleic acid and protein sequences described herein can further be used as "query sequences" to perform searches against public databases, e.g., to identify related sequences. Such searches can be performed with the NBLAST and XBLAST programs (version 2.0) of Altschul, et al. (1990) (J. Mol. Biol. 215: 403-10). BLAST nucleotide searches can be performed with the NBLAST program, score=100, wordlength=12, to obtain nucleotide sequences identical to the nucleic acid molecules described herein. BLAST protein searches can be performed with the XBLAST program, score=50, worldlength=3, to obtain amino acid sequences identical to the proteins described herein. To obtain gapped alignments for comparison purposes, gapped BLAST can be used as described in Altschul et al. (1997) Nucleic Acids Res. 25(17):3389-3402. When utilizing BLAST and Gapped BLAST programs, the default parameters of the respective programs (e.g., XBLAST and NBLAST) can be used. See www.ncbi.nlm.nih.gov.

[0126] These nucleic acids may be present in whole cells, in a cell lysate, or in a partially purified or substantially pure form. A nucleic acid is "isolated" or "substantially pure" when it is purified away from other cellular components or other contaminants, such as other cellular nucleic acids (e.g., other parts of chromosomes) or proteins, by conventional techniques, including alkaline / SDS treatment, CsCl banding, column chromatography, agarose gel electrophoresis, and others well known in the art. See F. Ausubel, et al., ed. Current Protocols in Molecular Biology, Greene Publishing and Wiley Interscience, New York (1987).

[0127] To provide gene sequence, nucleic acid, for example cDNA, may be mutated according to standard techniques.For coding sequences, these mutations can affect amino acid sequence as desired.Specifically, DNA sequences substantially identical to or derived from native V, D, J, constant, switch and other such sequences described herein are intended.

[0128] The term "vector", as used herein, is intended to refer to a nucleic acid molecule capable of transporting another nucleic acid to which it has been linked. One type of vector is a "plasmid", which means a circular double stranded DNA loop into which other DNA segments can be ligated. Another type of vector is a viral vector, in which other DNA segments can be ligated into the viral genome. Some vectors are capable of autonomous replication in a host cell into which they are introduced (e.g., bacterial vectors having a bacterial origin of replication and episomal mammalian vectors). Other vectors (e.g., non-episomal mammalian vectors) can be integrated into the genome of a host cell upon introduction into the host cell, and thereby are replicated along with the host genome. In addition, certain vectors are capable of directing the expression of genes to which they are operatively linked. Such vectors are referred to herein as "recombinant expression vectors" (or simply "expression vectors"). In general, expression vectors used in recombinant DNA techniques are often in the form of plasmids. In this description, "plasmid" and "vector" can be used interchangeably, as the plasmid is the most commonly used form of vector. However, also included are other forms of expression vectors, such as viral vectors (eg, replication defective retroviruses, adenoviruses and adeno-associated viruses), which serve equivalent functions.

[0129] As used herein, the term "recombinant host cell" (or simply "host cell") is intended to refer to a cell that contains a nucleic acid that is not naturally occurring in the cell, and may be a cell into which a recombinant expression vector has been introduced. It should be understood that such terms are intended to refer not only to the specific subject cell, but also to the progeny of such a cell. Since certain modifications may occur in successive generations, either by mutation or environmental influences, such progeny may not, in fact, be identical to the parent cell, but are still included within the scope of the term "host cell" as used herein.

[0130] As used herein, the term "antigen" refers to any natural or synthetic immunogenic substance, such as a protein, peptide, or hapten. The antigen may be CD73 or a fragment thereof.

[0131] "Immune response" refers to a biological response in a vertebrate to exogenous substances, such a response protects the organism against these substances and the diseases caused by them. Immune response is mediated by the action of cells of the immune system (e.g., T lymphocytes, B lymphocytes, natural killer (NK) cells, macrophages, eosinophils, mast cells, dendritic cells or neutrophils) and soluble macromolecules produced by either these cells or the liver (including antibodies, cytokines, and complement), which results in selective targeting, binding, damage, destruction, and / or elimination of invading pathogens, cells or tissues of vertebrate organs infected with pathogens, cancerous or other abnormal cells, or normal human cells or tissues in the case of autoimmunity or pathological inflammation. Immune responses or reactions include, for example, activation or inhibition of T cells, e.g., effector T cells, or Th cells such as CD4+ or CD8+ T cells, or inhibition of Treg cells.

[0132] "Immunomodulator" or "immunomodulator" refers to a substance, such as a component of a signaling pathway, that may be involved in modulating, regulating, or altering an immune response. "Modulating," "modulating," or "altering" an immune response refers to any change in the cells of the immune system or the activity of such cells (e.g., effector T cells). Such modulation includes stimulation or suppression of the immune system, which may be manifested by increasing or decreasing the number of various cell types, increasing or decreasing the activity of these cells, or any other alteration that may occur within the immune system. Both suppressive and stimulatory immunomodulators have been identified, some of which may have enhanced function in the tumor microenvironment. Immunomodulators may be present on the surface of T cells. "Immunomodulatory target" or "immunomodulatory target" is an immunomodulator that targets a bond whose activity is altered by the binding of a substance, agent, moiety, compound, or molecule. Immunomodulatory targets include, for example, receptors ("immunomodulatory receptors") and receptor ligands ("immunomodulatory ligands") on the surface of cells.

[0133] The increased ability to stimulate an immune response or the immune system may be due to the enhanced agonist activity of T cell costimulatory receptors and / or the enhanced antagonist activity of inhibitory receptors. The increased ability to stimulate an immune response or the immune system may be reflected by an increased time of EC50 or maximum level of immune response in assays measuring immune responses, such as changes in cytokine or chemokine release, cytokine activity (directly determined on target cells or indirectly determined through detection of CD 107a or granzymes) and spreading. The ability to stimulate an immune response or immune system activity may be enhanced by at least 10%, 30%, 50%, 75%, 2 times, 3 times, 5 times or more.

[0134] "Immunotherapy" means the treatment of a subject suffering from a disease, or suffering from or at risk of suffering from a recurrence of a disease, by methods involving inducing, enhancing, suppressing or otherwise modifying the immune response.

[0135] "Immuno stimulating therapy" or "immuno stimulatory therapy" refers to a therapy that increases (induces or enhances) the immune response in a subject, for example to treat cancer.

[0136] "Enhancing an endogenous immune response" means increasing the efficacy or potency of an immune response present in a subject. This increased efficacy and potency can be achieved, for example, by overcoming mechanisms that suppress the endogenous host immune response or by stimulating mechanisms that enhance the endogenous host immune response.

[0137] "T effector" ("Teff") cells refer to T cells (e.g., CD4+ and CD8+ T cells) as well as T helper (Th) cells that have cytolytic activity, secrete cytokines, and activate and induce other immune cells, but do not include regulatory T cells (Treg cells).

[0138] The term "linkage" as used herein means the association of two or more molecules. Linkage may be covalent or non-covalent. Linkage may also be genetic (i.e., recombinantly fused). Such linkage may be accomplished using widely known techniques such as chemical conjugation and recombinant protein production.

[0139] As used herein, "administering" refers to the physical introduction of a composition containing a therapeutic agent into a subject using any of a variety of methods and delivery systems known to those skilled in the art. Preferred routes of administration of the antibodies described herein include intravenous, intraperitoneal, intramuscular, subcutaneous, spinal or other parenteral routes of administration, such as administration by injection or infusion. The term "parenteral administration" as used herein refers to modes of administration other than enteral and topical administration, usually by injection, including, but not limited to, intravenous, intraperitoneal, intramuscular, intraarterial, intrathecal, intralymphatic, intralesional, intracapsular, intraorbital, intracardiac, intradermal, intratracheal, subcutaneous, subcuticular, intraarticular, subcapsular (subcapsular), subarachnoid, intrathecal, epidural and intrasternal injection and infusion, and in vivo electroporation. Alternatively, the antibodies described herein can be administered parenterally, such as topically, epidermally or mucosally, such as intranasally, orally, intravaginally, rectally, sublingually or topically. Administration can be, for example, once, multiple times, and / or over one or more extended periods of time.

[0140] As used herein, the term "T cell-mediated response" refers to a response mediated by T cells, including effector T cells (e.g., CD8+ cells) and helper T cells (e.g., CD4+ cells), and T cell-mediated responses include, for example, T cell cytotoxicity and proliferation.

[0141] As used herein, the term "cytotoxic T lymphocyte (CTL) response" refers to an immune response induced by cytotoxic T cells. CTL responses are primarily mediated by CD8+ T cells.

[0142] As used herein, the terms "inhibition" or "blocking (eg, referring to inhibition / blocking of CD73 binding or activity)" are used interchangeably and encompass both partial and complete inhibition / blocking.

[0143] As used herein, "cancer" refers to a broad group of diseases characterized by the uncontrolled growth of abnormal cells in the body. Unregulated cell division can result in the formation of malignant tumors or cells that can invade nearby tissues and metastasize to distant sites in the body via the lymphatic system or bloodstream.

[0144] As used herein, the terms "treat", "treating" and "treatment" refer to any type of intervention or process performed or administered to a subject for the purpose of reversing, alleviating, ameliorating, inhibiting, or slowing or preventing the progression, development, severity or recurrence of symptoms, complications, conditions or biochemical indicators associated with a disease. Prevention means administration to a subject not suffering from a disease to prevent the disease from occurring or minimize its effects, if any.

[0145] "Hematologic malignancies" include lymphomas, leukemias, myelomas, or lymphatic malignancies, as well as cancers of the spleen and lymph nodes. Exemplary lymphomas include both B-cell and T-cell lymphomas. B-cell lymphomas include both Hodgkin's lymphoma and most non-Hodgkin's lymphomas. Non-limiting examples of B-cell lymphomas include diffuse large B-cell lymphoma, follicular lymphoma, mucosa-associated lymphoid tissue lymphoma, small lymphocytic lymphoma (overlap with chronic lymphocytic leukemia), mantle cell lymphoma (MCL), Burkitt's lymphoma, mediastinal large B-cell lymphoma, Waldenstrom's macroglobulinemia, nodal marginal zone B-cell lymphoma, splenic marginal zone lymphoma, intravascular large B-cell lymphoma, primary effusion lymphoma, and lymphomatoid granulomatosis. Non-limiting examples of T-cell lymphoma include extranodal T-cell lymphoma, cutaneous T-cell lymphoma, anaplastic large cell lymphoma, and angioimmunoblastic T-cell lymphoma. Hematological malignancies also include, but are not limited to, leukemias, such as secondary leukemia, chronic lymphocytic leukemia, acute myeloid leukemia, chronic myelogenous leukemia, and acute lymphoblastic leukemia. Hematological malignancies further include, but are not limited to, myelomas, such as multiple myeloma and smoldering multiple myeloma. Other hematological and / or B-cell or T-cell related cancers are encompassed by the term hematological malignancies.

[0146] The term "effective dose" or "effective dosage" is defined as an amount sufficient to achieve or at least partially achieve a desired effect. A "therapeutically effective dose" or "therapeutically effective dosage" of a drug or therapeutic agent is any amount of the drug that, when used alone or in combination with another therapeutic agent, promotes regression of a disease as evidenced by a decrease in the severity of disease symptoms, an increase in the frequency and duration of disease symptom-free periods, or the prevention of disability or injury due to disease affliction. A "prophylactically effective dose" or "prophylactically effective dosage" of a drug is an amount of the drug that, when administered alone or in combination with another therapeutic agent, to a subject at risk of developing a disease or at risk of suffering a recurrence of the disease, inhibits the onset or recurrence of the disease. The ability of a therapeutic or prophylactic agent to promote regression of a disease or inhibit the onset or recurrence of a disease can be evaluated using various methods known to those skilled in the art by assaying the activity of the agent in an animal model system predictive of efficacy in humans, such as in human subjects during clinical trials, or in an in vitro assay.

[0147] As an example, an anti-cancer drug is a drug that slows the progression of cancer or promotes the regression of cancer in a subject. In a preferred embodiment, a therapeutically effective amount of a drug promotes the regression of cancer to the point of eliminating the cancer. "Promoting cancer regression" means that administering an effective amount of a drug, alone or in combination with an anti-tumor drug, results in a decrease in tumor growth or size, tumor necrosis, a decrease in the severity of at least one disease symptom, an increase in the frequency and duration of disease symptom-free periods, prevention of disability or impairment due to disease affliction, or otherwise amelioration of disease symptoms. Pharmacological efficacy refers to a drug's ability to promote a patient's cancer regression coefficient. Physiological safety refers to an acceptably low level of toxicity or other adverse physiological effects (adverse effects) at the cell, organ and / or organism level resulting from administration of the drug.

[0148] For example, for the treatment of tumors, a therapeutically effective dose or administration of a drug preferably inhibits cell proliferation or tumor growth by at least about 20%, more preferably at least about 40%, even more preferably at least about 60%, and even more preferably at least about 80% relative to untreated subjects. In the most preferred embodiment, a therapeutically effective dose or administration of a drug completely inhibits cell proliferation or tumor growth, i.e., preferably inhibits cell proliferation or tumor growth by 100%. The tumor growth inhibition ability of a compound can be evaluated using the assays described above. Alternatively, this characteristic of the composition can be evaluated by testing the ability of the compound to inhibit cell proliferation, and such inhibition can be measured in vitro by assays known to those skilled in the art. In other preferred embodiments described herein, tumor regression can be observed and can last for at least about 20 days, more preferably at least about 40 days, or even more preferably at least about 60 days.

[0149] The terms "patient" and "subject" refer to any human or non-human animal that receives either preventive or therapeutic treatment. For example, the methods and compositions described herein can be used to treat subjects with cancer. The term "non-human animal" includes all vertebrates, such as mammals and non-human primates, sheep, dogs, cows, chickens, amphibians, reptiles, etc.

[0150] "Pharmaceutically acceptable" is intended to refer to a substance or composition that must be chemically and / or toxicologically compatible with the other ingredients comprising the formulation and / or the mammal being treated therewith.

[0151] "Pharmaceutically acceptable vector" encompasses pharma- ceutically acceptable vectors, excipients, and diluents, and is intended to refer to any material, composition, or vehicle, including a liquid or solid filler, diluent, excipient, solvent, or encapsulating material, that carries or transports a pharmaceutical agent from one organ or body part to another organ or body part of a subject. EXAMPLES

[0152] Example 1: Screening and identification of anti-CD73 antibodies C57 / BL6 mice were immunized with human CD73 ecto-domain recombinant protein (huCD73, SEQ ID NO: 1). The first immunization (intraperitoneal injection) was performed with an emulsion of 50 μg huCD73 protein + Freund's complete adjuvant, the second immunization (subcutaneous injection) was performed with an emulsion of 25 μg huCD73 protein + Freund's incomplete adjuvant, the third immunization (intraperitoneal injection) was performed with an emulsion of 25 μg huCD73 protein + Freund's incomplete adjuvant, the fourth immunization (subcutaneous injection) was performed with an emulsion of 25 μg huCD73 protein + Freund's incomplete adjuvant, and finally a final boost immunization (intraperitoneal injection) was performed with 50 μg huCD73 protein. Four days after the boost immunization, the immune spleen cells were fused with SP2 / 0 cells by electrofusion to prepare hybridoma cells. Mice were immunized in the same manner to prepare phage library antibodies. Through primary screening by ELISA and flow cytometry, 32 hybridoma antibodies and 2 phage antibodies were obtained, which bound to human CD73 and cynomolgus monkey CD73, and then further screening for blockade enzyme activity was performed using 293T / 17 cells expressing huCD73 (293T / 17-huCD73), and finally 5 clones with the function of blocking CD73 enzyme activity were obtained.

[0153] Example 2: Indirect assay of antibody binding to CD73 by ELISA Indirect ELISA was used to evaluate the binding ability of each positive clone to soluble huCD73 protein. Soluble huCD73 was coated, gradient dilution samples were incubated, HPR-labeled secondary antibody was added, and finally TMB was added to develop color, and OD450 was read at the end. As shown in Figure 1, all three cloned antibodies, 66F2A8D6 (SEQ ID NO: 118 and 119), 94A12G11F2 (SEQ ID NO: 120 and 121), 191C3A8B9 (SEQ ID NO: 122 and 123), and all two phage antibodies, S1B5 (SEQ ID NO: 13 and 14) and JB24Chi (SEQ ID NO: 26 and 28), were shown to bind to soluble recombinant CD73 with sub-nanomolar affinity.

[0154] Table 1: Binding ability of positive clones to soluble huCD73 protein. [Table 1]

[0155] Example 3: Assaying antibody binding to native CD73 cell surface by flow cytometry 293T / 17-huCD73 cells were used to evaluate the binding ability of five antibodies to native CD73 on the cell surface. After incubation of gradient-diluted antibodies with 293T / 17-huCD73 cells, fluorescently labeled antibodies were added, and the fluorescence intensity values ​​were read and EC 50 As shown in Figure 2, all antibodies were shown to bind to cell surface CD73 with nanomolar or subnanomolar affinity. Table 2: Binding ability of positive clones to native CD73 protein [Table 2]

[0156] Example 4: Study of blocking of soluble CD73 recombinant protease activity This assay evaluates the blocking ability of CD73 antibodies against the 5' exonuclease of soluble huCD73 recombinant protease. Upon antibody binding, the activity of huCD73 recombinant protein to hydrolyze AMP to adenosine and inorganic phosphate is blocked. Meanwhile, the competition between AMP and ATP inhibits the ability of luciferase to emit light. Thus, blocking antibodies attenuate the luminescence, resulting in a decrease in the RLU value. As shown in Figure 3, 66F2A8D6, 94A12G11F2, 191C3A8B9, antibodies S1B5 and JB24Chi all have an inhibitory effect on the activity of soluble CD73 recombinant protein, and the IC 50 were at nanomolar or subnanomolar levels. Table 3: Inhibitory ability of CD73 antibodies against soluble CD73 recombinant protease activity [Table 3]

[0157] Example 5: Blockade of 5' exonuclease activity of cell surface antibodies against CD73 This method was based on 293T / 17-huCD73 and 293T / 17-cynoCD73 cells to evaluate the blocking ability of CD73 antibodies against 5' exonuclease on cell surface activity, and further confirmed the biochemical activity of five antibodies. As shown in Figure 4, all antibodies could inhibit 5' exonuclease on cell surface activity. Among them, the inhibitory activity of 191C3A8B9 against huCD73 was weaker compared with cynomolgus CD73, while the others had similar inhibitory activity against human / cynomolgus CD73. The IC of all antibodies 50 is 10 -11 ~10 -12 M (Table 4). [Table 4] 5' exonuclease inhibitory activity of cell surface-activated CD73 antibodies [Table 4]

[0158] Example 6: Reverse effect of CD73 antibody on AMP-mediated inhibition of human CD4+ T cell proliferation The antibody blocked the enzymatic activity of CD73 and inhibited the production of adenosine, thereby relieving the proliferation inhibition of human CD4+ T cells adenosine. By this method, the ability of CD73 antibody to relieve AMP-mediated CD4+ T cell proliferation inhibition was confirmed in vitro, and at the same time, the blocking of CD73 antibody against CD4+ T cell CD73 was detected by CellTiter-Glo (Promega) reagent, and the IFN-γ level in the cell culture supernatant was detected by ELISA.

[0159] As a result, 66F2A8D6, 94A12G11F2, S1B5, and JB24Chi were able to reverse AMP-mediated suppression of CD4+ T cell proliferation (Figure 5), and EC 50 is 10 -11 ~10 -12 M (Table 5) were all relatively similar. Table 5 Ability of CD73 antibodies to reverse AMP-mediated inhibition of human CD4+ T cell proliferation [Table 5]

[0160] Similar to the results of the CD4+ T cell proliferation experiment, 66F2A8D6, 94A12G11F2, S1B5, and JB24Chi all showed strong enzyme activity inhibitory effects (Figure 6), with inhibitory potency of 10 -11 ~10 -12 M (Table 6). Table 6 Ability of antibodies to block CD4+ T cells [Table 6]

[0161] As shown in Figure 7, the supernatant IFN-γ was detected using an ELISA detection kit (Dakewe), and 66F2A8D6, 94A12G11F2, S1B5 and JB24Chi were able to stimulate CD4+ T cells to release IFN-γ, and each antibody-stimulated T cell was able to secrete ECs that secreted IFN-γ. 50 is 10-11 ~10 -12 The results were within the range of M (Table 7). Table 7 Ability of antibodies to reverse IFN-γ release from CD4+ T cells [Table 7]

[0162] Example 7: CD73 antibody-mediated CD73 internalization experiments The internalization effect of 66-IgG2 (SEQ ID NOs: 39 and 40), 94-IgG2 (SEQ ID NOs: 51 and 53), S1B5, and JB24Chi antibodies into MDA-MB-231 cells was detected using Fab-ZAP saporin conjugate (Advanced Targeting Systems). As shown in Figure 8, all four chimeric antibodies mediated the internalization effect of CD73 in a dose-dependent manner, and the IC 50 is about 10 -11 It was M. Table 8. Ability of antibody-mediated internalization of CD73 [Table 8]

[0163] Example 8: Humanization of antibodies The CDR and framework regions are numbered, and the amino acids of each antibody in the CDR and framework regions are numbered according to the Kabat system (see Table I). Two antibodies, 94A12E7D5 and JB24Chi, were humanized by CDR grafting. The sequence identity and structural similarity of the two mouse and human antibodies were analyzed, respectively, and the CDRs of the mouse antibodies were grafted into a series of human antibody templates based on the above. After preliminary screening by ELISA, three humanized antibodies of JB24Chi and three humanized antibodies of 94A12E7D5 were obtained, which were named JB24H2L1 (SEQ ID NO: 71 and 73), JB24H3L2 (SEQ ID NO: 72 and 74), JB24H3L3 (SEQ ID NO: 72 and 75), JB94H1L3 (SEQ ID NO: 81 and 85), JB94H2L1 (SEQ ID NO: 82 and 84), and JB94H3L3 (SEQ ID NO: 83 and 85), respectively. The chimeric antibody consisting of 94A12G11F and the Fv of a mouse-derived human IgG1 antibody and a human κ constant region was designated JB94Chi (SEQ ID NOs: 52 and 53).

[0164] Example 9: Affinity assays of humanized and chimeric antibodies Affinity of humanized antibodies determined by indirect ELISA: 96-well ELISA plates were coated with 1μg / ml CD73 recombinant protein, 50ul / well, washed 3 times with 200ul / well PBST, blocked with 200ul / well of 1% BSA at room temperature for 1 hour, and washed 3 times with 200ul / well PBST. Incubated with 100μL / well of gradient diluted antibody for 1 hour at room temperature. After washing the plate 3 times with 200ul / well PBST, 100ul of HRP-labeled secondary antibody diluted at 1:5000 was added to each well, and the plate was incubated for 1 hour at room temperature. The plate was washed 3 times with 200ul / well PBST, and 100ul of TMB was added to each well and incubated for 5 minutes at room temperature in the dark. OD values ​​were read at 530nm excitation, 590nm emission, and 570nm cutoff. The results are shown in FIG. 9, and the affinities of the humanized antibody and the parent antibody were similar to the antigen (Table 9). Table 9. Affinity of humanized antibodies to soluble huCD73 [Table 9]

[0165] Flow cytometry assay: 293T / 17 cells expressing huCD73 or cynoCD73 were used to evaluate the binding capacity of the humanized antibodies. 2x10 cells resuspended in PBS buffer were used. 6 The cells were distributed into 96-well plates and incubated with gradient diluted humanized antibodies for 1 h at 4°C or on ice, after which the cells were centrifuged at 1500 rpm for 3 min at 4°C, washed three times with PBS, and incubated with diluted APC-labeled goat anti-human polyclonal antibody (Biolegend) for 30 min in a refrigerator at 4°C. Finally, the cells were washed three times with PBS as above and analyzed on a MACSQuant flow cytometer. Data graphs and statistical affinity data were generated using GraphPad Prism software. As shown in Figure 10, the humanized antibodies JB24Chi and 94A12G11F had similar EC values ​​as their parental antibodies. 50 value, both 10 -11 M to 10 -12 The mean age of the patients was 18.6 years and the mean age of the patients was 18.6 years (Table 10). Table 10. Affinities of humanized and chimeric antibodies to cell surface huCD73 and cynoCD73 antigens [Table 10]

[0166] Example 10: Blocking 5' exonuclease activity of cell surface against humanized antibodies This method uses 293T / 17-huCD73 cells to evaluate the hydrolysis of AMP inhibited by CD73 to further confirm the biochemical activity of the humanized antibodies. As shown in Figure 11, the enzymatic blocking activity of all humanized antibodies, JB24H3L3, JB94H1L3, and 94H1L3 hIgG2 (SEQ ID NOs: 85 and 124), was 10 -11 ~10 -12 were at the level of M (Table 11). Table 11. Blocking activity of cell surface active 5' exonuclease for humanized antibodies [Table 11]

[0167] In addition, U87-MG cells were used to evaluate AMP hydrolysis catalyzed by CD73 and further confirm the biochemical activity of the humanized antibody. U87-MG cells were digested with trypsin and then cultured in MEM medium at a cell density of 4 × 10 5 The cells were adjusted to cells / ml and 50 μl / well was added to a 96-well plate. Humanized antibodies were gradient diluted in MEM medium and 50 μl / well was added to the wells and incubated at 37°C for 1 h. 100 μl of 360 μM AMP was added to each well and incubated at 37°C for 1 h. The plate was then centrifuged at 1500 rpm for 3 min, and an aliquot of the culture supernatant was transferred to an opaque 96-well flat-bottom plate (Costar, 3912) and 2X ATP was added to a final reaction concentration of 25 μM. Finally, a corresponding volume of CellTiter Glo reagent was added in a 1:1 ratio according to the Promega instructions. After equilibration at room temperature for 5 min, luminescence was read on a Perkin-Elmer Envision microplate reader and ATP levels were measured to determine cellular CD73 enzyme activity. Data graphs and statistical enzyme kinetic data were generated using GraphPad Prism software. The blocking activity of the humanized antibodies JB24Chi and JB94Chi is shown in Figure 12. 50 All of the values ​​are in the subnanomolar range (Table 12). Table 12. Blocking ability of 5' exonuclease activity of U87-MG cells against humanized antibodies

[0168] [Table 12]

[0169] Example 11: Reverse effect of humanized antibodies on AMP-mediated inhibition of human CD4+ T cell proliferation This method confirmed the ability of the humanized CD73 antibody to relieve AMP-mediated inhibition of CD4+ T cell proliferation in vitro, and simultaneously detected the blocking ability of the humanized antibody against CD4+ T cell CD73 enzyme activity using CellTiter-Glo (Promega) reagent, and detected the IFN-γ level in the cell culture supernatant by ELISA.

[0170] The activity results of the humanized antibodies JB24Chi and JB94Chi are shown in FIG. 13. Among these, the activities of JB94H1L3, 94H1L3 hIgG2, and JB94H3L3 were approximately 10 -11 ~10 -12 M (Table 13). Table 13. Ability of humanized antibodies to reverse AMP-mediated inhibition of human CD4+ T cell proliferation [Table 13]

[0171] The cell supernatant IFN-γ levels were detected using an ELISA detection kit (Dakewe). As shown in FIG. 14, each humanized antibody, except for JB24H3L3, showed a 10 -11 ~10 -12 M's EC 50 T cells were stimulated to secrete IFN-γ with (Table 14). Table 14. Ability of humanized Cd73 antibodies to reverse IFN-γ release from CD4+ T cells [Table 14]

[0172] Example 12: Inhibition of 5' exonuclease activity in the A375 xenograft model by humanized antibodies B-NDG mice (Biocytogen) were inoculated subcutaneously with A375 cells and 3 days later were injected intraperitoneally (ip) with antibodies JB94H1L3, 94H3L3 hIgG1 (sequence numbers 91 and 85) or PBS twice a week for 2 weeks. Tumors were harvested 1, 2, 3, and 7 days after administration. Fresh tissues were quickly frozen in small cups filled with liquid nitrogen, embedded in OCT, cut into 5-6 μm thick sections, and dried at room temperature. Tumor slices were fixed in pre-cooled acetone at 4 °C for 20 min. After drying, they were stored at -80 °C. Tumor slices were removed from the -80 °C refrigerator, equilibrated at room temperature for 5-10 min, and then fixed in 50 mM Tris-maleic acid buffer (PH 7.4, 2 mM CaCl 2 and 0.25 M sucrose) and preincubated at room temperature for 1 hour. After 1 hour, the incubation buffer was removed and the cells were again incubated in 50 mM Tris-maleate buffer (pH 7.4, 5 mM MnCl 2 , 2 mM lead nitrate, 2.5% dextran T200, 2.5 mM levamisole, and 400 μM AMP) was added, incubated at 37°C for 1.5 hours, washed three times with water, and the sections were soaked in 1% (NH 4 ) 2 After incubation with S for 1 min at room temperature, sections were quickly washed 3 times with water, counterstained with hematoxylin and eosin, dehydrated xylene clearing solution, and photographed under a microscope. Brown indicates the presence of activated CD73, and lack of brown indicates that the antibody blocks the activity of CD73. The results are shown in Figure 15A and Figure 15B.

[0173] These results suggest that JB94H1L3 and 94H3L3 hIgG1 significantly reduced 5' exonuclease activity in tumors in xenograft animal models, and that this was related to the timing of administration. On day 3 after discontinuation, CD73 enzyme activity in the JB94H1L3 treatment group decreased to its lowest point, and then increased slightly on day 7. CD73 enzyme activity in the 94H3L3 hIgG1 treatment group gradually increased from day 1 after administration. In summary, both antibodies had a good inhibitory effect on CD73 activity.

[0174] Example 13: Tumor-inhibitory effect of humanized antibodies against A375 human melanoma xenograft model A375 human melanoma cells were inoculated subcutaneously into the right hypochondrium of NCG mice, and PBMCs were resuspended in PBS before inoculation into the mice. 3 When the tumors grew to 50-100 mm, they were divided into two groups and given JB94H1L3 (10 mg / kg) or a solvent control. Tumor volume was measured twice a week using a caliper to measure the long and short diameters of the tumor. The volume was calculated using the formula: volume = 0.5 x long diameter x short diameter. 2 As shown in Figure 16, JB94H1L3 exhibited a significant tumor growth inhibitory effect.

[0175] These results were obtained using the following materials and methods: Antibody preparations: Preparation of hybridoma antibodies: Thawed hybridoma cells were cultured in 10% FBS-containing DMEM medium for 7 to 10 days, and the cell culture supernatant was collected and centrifuged at 1000 rpm for 10 minutes. The supernatant was purified with Protein G HP Spin Trap (GE Healthcare). Quantification was performed using a UV5nano (Millipore) spectrophotometer.

[0176] Recombinant antibody: 6 × 10 ExpiCHO cells (Thermo Fisher Scientific) with a viability of 99% 6 The cells were centrifuged at 1500 rpm for 5 minutes and resuspended. Expression vector dilutions, ExpiFectamine CHO reagent dilutions, and DNA-ExpiFectamine CHO complexes were prepared according to the manufacturer's instructions, and the DNA-ExpiFectamine complexes were transferred to the cell culture medium. Incubate in a culture medium containing 8% CO 2 Incubate in a shaker at 37°C for 8 days. Centrifuge at 11,000 rpm for 10 min to collect cell supernatant. Antibodies were purified using an NGC chromatography system (Bio-Rad) and rProtein G Beads 4FF pre-assembled columns. Quantification was performed using a UV5nano (Millipore) spectrophotometer.

[0177] Assay 1: Indirect ELISA 1ug / ml of recombinant CD73 protein was applied to an ELISA plate (Coning) and incubated overnight at 4℃. The next day, the plate was washed five times with PBS, blocked with 200ul / well of 2% skim milk, and incubated with a range of doses of CD73 antibody for 1 hour at room temperature. The plate was washed five times with PBST washing buffer (PBS, 0.05% Tween 20), HRP-conjugated goat anti-mouse IgG (H+L) (Promega) was added, incubated for 1 hour at room temperature, and anti-CD73 antibody was detected; the plate was washed five times, and TMB (Life Technologies) was added again to develop the color for 5-10 minutes, and finally 1N HCL was added to stop the reaction, and the OD value was measured at 450nm. Data graphs and statistical affinity data were generated using GraphPad Prism software.

[0178] Assay 2: Flow cytometry 100 μL of 2 × 10 cells expressing huCD73 (293T / 17-huCD73), cynoCD73 (293T / 17-cynoCD73), or moCD73 (293T / 17-moCD73) 5 Cells / well were added to a U-shaped 96-well cell culture plate. The samples to be tested were gradient diluted and incubated at 4°C for 1 hour. After washing, 100 μL of APC-labeled secondary antibody was added to each well and incubated for 30 minutes. After washing, the fluorescence was detected and read on the instrument. Data graphs and statistical affinity data were generated using GraphPad Prism software.

[0179] Construction of recombinant host cells 293T / 17-huCD73, 293T / 17-cynoCD73, 293T / 17-moD73: PLVX-EF1a viral vectors carrying huCD73, cynoCD73 and moCD73 genes and puromycin resistance were transfected into 293T / 17 cells using TransIT®-293 transfection reagent, and about 2 days later, the complete medium containing puromycin was replaced and cultured. After the cells were grown and cultured, single clone cells were selected using limited gradient dilution, and PE-labeled anti-huCD73, cynoCD73 and moCD73 antibodies were used to detect cell surface antigens after transfection. The cells were then grown and cultured for enzyme activity assay and flow cytometry.

[0180] Assay 3: Soluble CD73 enzyme activity inhibition test Based on soluble CD73 recombinant protein, blocking function of enzyme activity by antibodies was measured. In the presence of 500ng / ml CD73 recombinant protein, a specific dose range of CD73 antibodies was added to a 96-well flat round-bottom plate and incubated at 37°C for 1 hour, and AMP and ATP were added to each well at final concentrations of 180uM and 25uM. After incubation at 37°C for 30 minutes, a certain amount of cell supernatant was transferred to a blank plate, and CellTiterr-Glo (Promega) containing luciferase was added to the above wells in a 1:1 ratio after equilibration at room temperature in the dark for 5 minutes. Finally, luminescence values ​​were measured using an Enspire microplate reader (Perkin Elmer). GraphPad Prism software was used to generate data graphs and statistics for enzyme kinetic data. The enzyme inhibition rate is evaluated as follows: ○ATP+AMP: Maximum luciferase inhibition (100%) ATP+AMP+CD73: No luciferase inhibition (0%) The formula for residual CD7 activity was assessed as follows: JPEG0007623706000044.jpg11170

[0181] Assay 4: Cellular CD73 activity inhibition test 293T / 17-huCD73 cells were digested and centrifuged at 1500 rpm for 3 min and the supernatant was discarded. Cells were resuspended in serum-free DMEM medium and counted with a Biorad TC20 cell counter. The cell density was adjusted and cells were spread in a 96-well plate at 8,000 cells, 50 uL / well, and 50 uL of the gradient diluted antibody solution was added to the corresponding wells and incubated at 37°C with 5% CO 2 After incubating in the incubator for 1 hour, add 100 uL at a final concentration of 180 uM and incubate at 37°C with 5% CO 2 After incubation in 500°C for 1 hour, the cell plate was centrifuged at 1500 rpm for 3 minutes, and an aliquot of culture supernatant was transferred to an opaque 96-well flat-bottom plate (Costar, 3912), followed by adding 2XATP solution to a final reaction concentration of 25uM. Finally, the corresponding volume of CellTiter Glo reagent was added in a 1:1 ratio according to Promega's instructions. After equilibrating at room temperature for 5 minutes, the luminescence was read on a Perkin-Elmer Envision microplate reader to measure ATP levels and determine the activity of CD73. Data graphs and statistical enzyme kinetic data were generated using GraphPad Prism software.

[0182] Assay 5: Fab ZAP endocytosis experiment On the first day, 2000 cells / well of MDA-MB-231 cells were plated in 96-well flat-bottom plates at 50ul / well and incubated at 37°C with 5% CO 2The plates were incubated overnight in 5% CO2. The next day, gradient dilutions of antibodies in a dose range were incubated with 80 nM Fab-ZAP reagent (Advanced Targeting Systems) for 30 min at room temperature to allow Fab-ZAP to bind to the antibodies to be tested, and the antibodies were premixed. 50 uL of the mixture was added to MDA-MB-231 cell wells and incubated at 37°C in 5% CO2 for 3 days. After that, the cell plates were removed and CTG reagent (Promega) was added to lyse the cells for 2 min, followed by equilibration at room temperature for 5 min. Luminescence was measured using an Enspire microplate reader (Perkin Elmer) and cell growth curves were analyzed by GraphPad Prism software.

Claims

1. 1. An isolated antibody or antigen-binding fragment thereof that specifically binds to CD73, comprising: a heavy chain variable region comprising HCDR1, HCDR2, HCDR3; and a light chain variable region comprising LCDR1, LCDR2, LCDR3: 1) (a) HCDR1 comprises the amino acid sequence of SEQ ID NO: 43, (b) HCDR2 comprises the amino acid sequence of SEQ ID NO: 44, (c) HCDR3 comprises the amino acid sequence of SEQ ID NO: 45, (d) LCDR1 comprises the amino acid sequence of SEQ ID NO: 48, (e) LCDR2 comprises the amino acid sequence of SEQ ID NO: 49, and (f) LCDR3 comprises the amino acid sequence of SEQ ID NO: 50; 2) (a) HCDR1 comprises the amino acid sequence of SEQ ID NO:5, (b) HCDR2 comprises the amino acid sequence of SEQ ID NO:6, (c) HCDR3 comprises the amino acid sequence of SEQ ID NO:7, (d) LCDR1 comprises the amino acid sequence of SEQ ID NO:10, (e) LCDR2 comprises the amino acid sequence of SEQ ID NO:11, and (f) LCDR3 comprises the amino acid sequence of SEQ ID NO:12; 3) (a) HCDR1 comprises the amino acid sequence of SEQ ID NO: 18, (b) HCDR2 comprises the amino acid sequence of SEQ ID NO: 19, (c) HCDR3 comprises the amino acid sequence of SEQ ID NO: 20, (d) LCDR1 comprises the amino acid sequence of SEQ ID NO: 23, (e) LCDR2 comprises the amino acid sequence of SEQ ID NO: 24, and (f) LCDR3 comprises the amino acid sequence of SEQ ID NO: 25; 4) (a) HCDR1 comprises the amino acid sequence of SEQ ID NO:31, (b) HCDR2 comprises the amino acid sequence of SEQ ID NO:32, (c) HCDR3 comprises the amino acid sequence of SEQ ID NO:33, (d) LCDR1 comprises the amino acid sequence of SEQ ID NO:36, (e) LCDR2 comprises the amino acid sequence of SEQ ID NO:37, and (f) LCDR3 comprises the amino acid sequence of SEQ ID NO:38; or 5) (a) HCDR1 comprises the amino acid sequence of SEQ ID NO:56, (b) HCDR2 comprises the amino acid sequence of SEQ ID NO:57, (c) HCDR3 comprises the amino acid sequence of SEQ ID NO:58, (d) LCDR1 comprises the amino acid sequence of SEQ ID NO:61, (e) LCDR2 comprises the amino acid sequence of SEQ ID NO:62, and (f) LCDR3 comprises the amino acid sequence of SEQ ID NO:63; An isolated antibody or antigen-binding fragment thereof.

2. 2. The isolated antibody or antigen-binding fragment thereof of claim 1, comprising: (i) a heavy chain variable region (VH) comprising an amino acid sequence having at least 85% identity to an amino acid sequence selected from the group consisting of SEQ ID NOs: 41, 76, 77, and 78; and a light chain variable region (VL) comprising an amino acid sequence having at least 85% identity to an amino acid sequence selected from the group consisting of SEQ ID NOs: 46, 79, and 80; (ii) a heavy chain variable region (VH) comprising an amino acid sequence having at least 85% identity to the amino acid sequence of SEQ ID NO: 3; and a light chain variable region (VL) comprising an amino acid sequence having at least 85% identity to the amino acid sequence of SEQ ID NO: 8; (iii) a heavy chain variable region (VH) comprising an amino acid sequence having at least 85% identity to the amino acid sequence of SEQ ID NO: 16; and a light chain variable region (VL) comprising an amino acid sequence having at least 85% identity to an amino acid sequence selected from the group consisting of SEQ ID NOs: 21, 68, 69, and 70; (iv) a heavy chain variable region (VH) comprising an amino acid sequence having at least 85% identity to the amino acid sequence of SEQ ID NO: 29; and a light chain variable region (VL) comprising an amino acid sequence having at least 85% identity to the amino acid sequence of SEQ ID NO: 34; (v) a heavy chain variable region (VH) comprising an amino acid sequence having at least 85% identity to the amino acid sequence of SEQ ID NO: 54; and a light chain variable region (VL) comprising an amino acid sequence having at least 85% identity to the amino acid sequence of SEQ ID NO: 59; Preferably, 1. An isolated antibody or antigen-binding fragment thereof, comprising: 1) a heavy chain variable region (VH) comprising an amino acid sequence having at least 85% identity to the amino acid sequence of SEQ ID NO:3, and a light chain variable region (VL) comprising an amino acid sequence having at least 85% identity to the amino acid sequence of SEQ ID NO:8; 2) a heavy chain variable region (VH) comprising an amino acid sequence having at least 85% identity to the amino acid sequence of SEQ ID NO: 16, and a light chain variable region (VL) comprising an amino acid sequence having at least 85% identity to the amino acid sequence of SEQ ID NO: 21; 3) a heavy chain variable region (VH) comprising an amino acid sequence having at least 85% identity to the amino acid sequence of SEQ ID NO: 29, and a light chain variable region (VL) comprising an amino acid sequence having at least 85% identity to the amino acid sequence of SEQ ID NO: 34; 4) a heavy chain variable region (VH) comprising an amino acid sequence having at least 85% identity to the amino acid sequence of SEQ ID NO: 41, and a light chain variable region (VL) comprising an amino acid sequence having at least 85% identity to the amino acid sequence of SEQ ID NO: 46; 5) a heavy chain variable region (VH) comprising an amino acid sequence having at least 85% identity to the amino acid sequence of SEQ ID NO: 54, and a light chain variable region (VL) comprising an amino acid sequence having at least 85% identity to the amino acid sequence of SEQ ID NO: 59; 6) a heavy chain variable region (VH) comprising an amino acid sequence having at least 85% identity to the amino acid sequence of SEQ ID NO: 76, and a light chain variable region (VL) comprising an amino acid sequence having at least 85% identity to the amino acid sequence of SEQ ID NO: 79; 7) a heavy chain variable region (VH) comprising an amino acid sequence having at least 85% identity to the amino acid sequence of SEQ ID NO: 76, and a light chain variable region (VL) comprising an amino acid sequence having at least 85% identity to the amino acid sequence of SEQ ID NO: 80; 8) a heavy chain variable region (VH) comprising an amino acid sequence having at least 85% identity to the amino acid sequence of SEQ ID NO: 77, and a light chain variable region (VL) comprising an amino acid sequence having at least 85% identity to the amino acid sequence of SEQ ID NO: 79; 9) a heavy chain variable region (VH) comprising an amino acid sequence having at least 85% identity to the amino acid sequence of SEQ ID NO: 77, and a light chain variable region (VL) comprising an amino acid sequence having at least 85% identity to the amino acid sequence of SEQ ID NO: 80; 10) a heavy chain variable region (VH) comprising an amino acid sequence having at least 85% identity to the amino acid sequence of SEQ ID NO: 78, and a light chain variable region (VL) comprising an amino acid sequence having at least 85% identity to the amino acid sequence of SEQ ID NO: 79; 11) A heavy chain variable region (VH) comprising an amino acid sequence having at least 85% identity to the amino acid sequence of SEQ ID NO: 78, and a light chain variable region (VL) comprising an amino acid sequence having at least 85% identity to the amino acid sequence of SEQ ID NO:

80.

3. The isolated antibody i) is an IgG; ii) is IgG1, IgG2 or IgG4; and / or iii) Monoclonal antibodies, chimeric antibodies, humanized antibodies, human engineered antibodies, Fv, single chain antibodies (scFv), Fab, Fab', Fab'-SH or F(ab'). 2 is An isolated antibody or antigen-binding fragment thereof according to any one of claims 1 to 2.

4. The isolated antibody or antigen-binding fragment thereof of any one of claims 1 to 3, comprising: (I) a heavy chain comprising an amino acid sequence having at least 85% identity to an amino acid sequence selected from the group consisting of SEQ ID NOs: 51, 52, 81, 82, 83, 86, 87, 90, 91, 120, 124, 125, 126, and 127; and a light chain comprising an amino acid sequence having at least 85% identity to an amino acid sequence selected from the group consisting of SEQ ID NOs: 53, 84, 85, 88, 89, and 121. (II) a heavy chain comprising an amino acid sequence having at least 85% identity to an amino acid sequence selected from the group consisting of SEQ ID NOs: 13 and 15; and a light chain comprising an amino acid sequence having at least 85% identity to the amino acid sequence of SEQ ID NO: 14; (III) a heavy chain comprising an amino acid sequence having at least 85% identity to an amino acid sequence selected from the group consisting of SEQ ID NOs: 26 and 27; and a light chain comprising an amino acid sequence having at least 85% identity to an amino acid sequence selected from the group consisting of SEQ ID NOs: 28, 74, and 75. (IV) a heavy chain comprising an amino acid sequence having at least 85% identity to an amino acid sequence selected from the group consisting of SEQ ID NOs: 39 and 118; and a light chain comprising an amino acid sequence having at least 85% identity to an amino acid sequence selected from the group consisting of SEQ ID NOs: 40 and 119. (V) a heavy chain comprising an amino acid sequence having at least 85% identity to an amino acid sequence selected from the group consisting of SEQ ID NOs: 64 and 122; and a light chain comprising an amino acid sequence having at least 85% identity to an amino acid sequence selected from the group consisting of SEQ ID NOs: 65 and 123. Preferably, 1. An isolated antibody or antigen-binding fragment thereof, comprising: 1) a heavy chain comprising an amino acid sequence having at least 85% identity to the amino acid sequence of SEQ ID NO: 13, and a light chain comprising an amino acid sequence having at least 85% identity to the amino acid sequence of SEQ ID NO: 14; 2) a heavy chain comprising an amino acid sequence having at least 85% identity to the amino acid sequence of SEQ ID NO: 15, and a light chain comprising an amino acid sequence having at least 85% identity to the amino acid sequence of SEQ ID NO: 14; 3) a heavy chain comprising an amino acid sequence having at least 85% identity to the amino acid sequence of SEQ ID NO:26, and a light chain comprising an amino acid sequence having at least 85% identity to the amino acid sequence of SEQ ID NO:28; 4) a heavy chain comprising an amino acid sequence having at least 85% identity to the amino acid sequence of SEQ ID NO:27, and a light chain comprising an amino acid sequence having at least 85% identity to the amino acid sequence of SEQ ID NO:28; 5) a heavy chain comprising an amino acid sequence having at least 85% identity to the amino acid sequence of SEQ ID NO: 39, and a light chain comprising an amino acid sequence having at least 85% identity to the amino acid sequence of SEQ ID NO: 40; 6) a heavy chain comprising an amino acid sequence having at least 85% identity to the amino acid sequence of SEQ ID NO:51, and a light chain comprising an amino acid sequence having at least 85% identity to the amino acid sequence of SEQ ID NO:53; 7) a heavy chain comprising an amino acid sequence having at least 85% identity to the amino acid sequence of SEQ ID NO:52, and a light chain comprising an amino acid sequence having at least 85% identity to the amino acid sequence of SEQ ID NO:53; 8) a heavy chain comprising an amino acid sequence having at least 85% identity to the amino acid sequence of SEQ ID NO:64, and a light chain comprising an amino acid sequence having at least 85% identity to the amino acid sequence of SEQ ID NO:65; 9) a heavy chain comprising an amino acid sequence having at least 85% identity to the amino acid sequence of SEQ ID NO: 81, and a light chain comprising an amino acid sequence having at least 85% identity to the amino acid sequence of SEQ ID NO: 84; 10) a heavy chain comprising an amino acid sequence having at least 85% identity to the amino acid sequence of SEQ ID NO: 81, and a light chain comprising an amino acid sequence having at least 85% identity to the amino acid sequence of SEQ ID NO: 85; 11) a heavy chain comprising an amino acid sequence having at least 85% identity to the amino acid sequence of SEQ ID NO: 82, and a light chain comprising an amino acid sequence having at least 85% identity to the amino acid sequence of SEQ ID NO: 84; 12) a heavy chain comprising an amino acid sequence having at least 85% identity to the amino acid sequence of SEQ ID NO: 82, and a light chain comprising an amino acid sequence having at least 85% identity to the amino acid sequence of SEQ ID NO: 85; 13) a heavy chain comprising an amino acid sequence having at least 85% identity to the amino acid sequence of SEQ ID NO: 83, and a light chain comprising an amino acid sequence having at least 85% identity to the amino acid sequence of SEQ ID NO: 84; 14) a heavy chain comprising an amino acid sequence having at least 85% identity to the amino acid sequence of SEQ ID NO: 83, and a light chain comprising an amino acid sequence having at least 85% identity to the amino acid sequence of SEQ ID NO: 85; 15) a heavy chain comprising an amino acid sequence having at least 85% identity to the amino acid sequence of SEQ ID NO: 90, and a light chain comprising an amino acid sequence having at least 85% identity to the amino acid sequence of SEQ ID NO: 84; 16) a heavy chain comprising an amino acid sequence having at least 85% identity to the amino acid sequence of SEQ ID NO: 90, and a light chain comprising an amino acid sequence having at least 85% identity to the amino acid sequence of SEQ ID NO: 85; 17) a heavy chain comprising an amino acid sequence having at least 85% identity to the amino acid sequence of SEQ ID NO: 91, and a light chain comprising an amino acid sequence having at least 85% identity to the amino acid sequence of SEQ ID NO: 84; 18) a heavy chain comprising an amino acid sequence having at least 85% identity to the amino acid sequence of SEQ ID NO: 91, and a light chain comprising an amino acid sequence having at least 85% identity to the amino acid sequence of SEQ ID NO: 85; 19) a heavy chain comprising an amino acid sequence having at least 85% identity to the amino acid sequence of SEQ ID NO: 86, and a light chain comprising an amino acid sequence having at least 85% identity to the amino acid sequence of SEQ ID NO: 88; 20) a heavy chain comprising an amino acid sequence having at least 85% identity to the amino acid sequence of SEQ ID NO: 86, and a light chain comprising an amino acid sequence having at least 85% identity to the amino acid sequence of SEQ ID NO: 89; 21) a heavy chain comprising an amino acid sequence having at least 85% identity to the amino acid sequence of SEQ ID NO: 87, and a light chain comprising an amino acid sequence having at least 85% identity to the amino acid sequence of SEQ ID NO: 88; 22) a heavy chain comprising an amino acid sequence having at least 85% identity to the amino acid sequence of SEQ ID NO: 87, and a light chain comprising an amino acid sequence having at least 85% identity to the amino acid sequence of SEQ ID NO: 89; 23) a heavy chain comprising an amino acid sequence having at least 85% identity to the amino acid sequence of SEQ ID NO: 124, and a light chain comprising an amino acid sequence having at least 85% identity to the amino acid sequence of SEQ ID NO: 84; 24) a heavy chain comprising an amino acid sequence having at least 85% identity to the amino acid sequence of SEQ ID NO: 124, and a light chain comprising an amino acid sequence having at least 85% identity to the amino acid sequence of SEQ ID NO: 85; 25) a heavy chain comprising an amino acid sequence having at least 85% identity to the amino acid sequence of SEQ ID NO: 125, and a light chain comprising an amino acid sequence having at least 85% identity to the amino acid sequence of SEQ ID NO: 84; or 26) a heavy chain comprising an amino acid sequence having at least 85% identity to the amino acid sequence of SEQ ID NO: 125, and a light chain comprising an amino acid sequence having at least 85% identity to the amino acid sequence of SEQ ID NO: 85; More preferably, d) comprising a heavy chain consisting of the amino acid sequence of SEQ ID NO: 81 and a light chain consisting of the amino acid sequence of SEQ ID NO: 85; e) comprising a heavy chain consisting of the amino acid sequence of SEQ ID NO: 82 and a light chain consisting of the amino acid sequence of SEQ ID NO: 84; f) comprising a heavy chain consisting of the amino acid sequence of SEQ ID NO: 83 and a light chain consisting of the amino acid sequence of SEQ ID NO: 85; g) comprising a heavy chain consisting of the amino acid sequence of SEQ ID NO: 124 and a light chain consisting of the amino acid sequence of SEQ ID NO: 85; or h) An isolated antibody or antigen-binding fragment thereof, comprising a heavy chain consisting of the amino acid sequence of SEQ ID NO: 125 and a light chain consisting of the amino acid sequence of SEQ ID NO:

85.

5. The isolated antibody or antigen-binding fragment thereof of any one of claims 1 to 4, wherein the isolated antibody or antigen-binding fragment thereof is an antagonist of CD73 or an antagonist of the 5'-nucleotidase of CD73, preferably wherein the CD73 is human CD73.

6. A medicament for reducing adenosine levels in a subject, for improving a T cell response in a subject, for stimulating an immune response in a subject, or for inhibiting the growth of tumor cells in a subject, comprising an isolated antibody or antigen-binding fragment thereof described in any one of claims 1 to 5.

7. The pharmaceutical composition of claim 6, wherein the subject is a tumor-bearing subject, and preferably the subject has tumor cells that express CD73 and / or a tumor microenvironment that contains CD73.

8. Use of the isolated antibody or antigen-binding fragment thereof according to any one of claims 1 to 5 in the manufacture of a medicament for reducing adenosine levels in tumor cells and / or the tumor microenvironment of a subject, for stimulating a T cell response in a tumor-bearing subject, for stimulating an immune response in a subject, or for inhibiting the proliferation of tumor cells in a subject.

9. The use according to claim 8, wherein the subject is a tumor-bearing subject, preferably the subject has tumor cells that express CD73 and / or a tumor microenvironment that contains CD73.

10. 6. The isolated antibody or antigen-binding fragment thereof of any one of claims 1 to 5, for use in reducing adenosine levels in tumor cells and / or the tumor microenvironment of a subject, for use in stimulating a T cell response in a tumor-bearing subject, for use in stimulating an immune response in a subject, or for inhibiting the proliferation of tumor cells in a subject.

11. The isolated antibody or antigen-binding fragment thereof of claim 10, wherein the subject is a tumor-bearing subject, preferably the subject has tumor cells that express CD73 and / or a tumor microenvironment that contains CD73.

12. A pharmaceutical composition comprising the isolated antibody or antigen-binding fragment thereof of any one of claims 1 to 5, and a pharma- ceutically acceptable excipient.

13. A medicament for treating a tumor, comprising the isolated antibody or antigen-binding fragment thereof according to any one of claims 1 to 5, or the pharmaceutical composition according to claim 12, Preferably, the tumor is selected from a solid tumor or a hematological tumor; More preferably, the tumor is selected from bladder cancer, breast cancer, cervical cancer, ovarian cancer, prostate cancer, testicular cancer, esophageal cancer, gastrointestinal cancer, pancreatic cancer, colorectal cancer, colon cancer, renal cancer, head and neck cancer, lung cancer (small cell lung cancer or non-small cell lung cancer), gastric cancer, bone cancer, liver cancer, thyroid cancer, skin cancer, central nervous system tumors, lymphoma, leukemia, myeloma, sarcoma, and virus-related cancer.

14. Use of the isolated antibody or antigen-binding fragment thereof according to any one of claims 1 to 5, or the pharmaceutical composition according to claim 12, for the manufacture of a medicament for treating a tumor, comprising: Preferably, the tumor is selected from a solid tumor or a hematological tumor; More preferably, the tumor is selected from bladder cancer, breast cancer, cervical cancer, ovarian cancer, prostate cancer, testicular cancer, esophageal cancer, gastrointestinal cancer, pancreatic cancer, colorectal cancer, colon cancer, renal cancer, head and neck cancer, lung cancer (small cell lung cancer or non-small cell lung cancer), gastric cancer, bone cancer, liver cancer, thyroid cancer, skin cancer, central nervous system tumors, lymphoma, leukemia, myeloma, sarcoma, and virus-associated cancer.

15. An isolated antibody or antigen-binding fragment thereof according to any one of claims 1 to 5 or a pharmaceutical composition according to claim 12 for use in the treatment of a tumor, comprising: Preferably, the tumor is selected from a solid tumor or a hematological tumor; More preferably, the isolated antibody or antigen-binding fragment thereof, or pharmaceutical composition is wherein the tumor is selected from bladder cancer, breast cancer, cervical cancer, ovarian cancer, prostate cancer, testicular cancer, esophageal cancer, gastrointestinal cancer, pancreatic cancer, colorectal cancer, colon cancer, renal cancer, head and neck cancer, lung cancer (small cell lung cancer or non-small cell lung cancer), gastric cancer, bone cancer, liver cancer, thyroid cancer, skin cancer, central nervous system tumors, lymphoma, leukemia, myeloma, sarcoma, and virus-associated cancer.

16. 1. A nucleic acid composition encoding an isolated antibody or antigen-binding fragment thereof that specifically binds to CD73, comprising: (I) a first nucleic acid comprising a nucleotide sequence selected from the group consisting of SEQ ID NOs: 42, 102, 103 and 104; and a second nucleic acid comprising a nucleotide sequence selected from the group consisting of SEQ ID NOs: 47, 105 and 106; (II) a first nucleic acid comprising the nucleotide sequence of SEQ ID NO:4; and a second nucleic acid comprising the nucleotide sequence of SEQ ID NO:9; (III) a first nucleic acid comprising the nucleotide sequence of SEQ ID NO: 17; and a second nucleic acid comprising a nucleotide sequence selected from the group consisting of SEQ ID NOs: 22, 94, 95 and 96; (IV) a first nucleic acid comprising the nucleotide sequence of SEQ ID NO:30; and a second nucleic acid comprising the nucleotide sequence of SEQ ID NO:35; (V) a first nucleic acid comprising the nucleotide sequence of SEQ ID NO:55; and a second nucleic acid comprising the nucleotide sequence of SEQ ID NO:60; or (VI) a first nucleic acid comprising a nucleotide sequence selected from the group consisting of SEQ ID NOs: 107, 108, 109, 112, 113, 116, and 117; and a second nucleic acid comprising a nucleotide sequence selected from the group consisting of SEQ ID NOs: 110, 111, 114, and 115; Preferably, A nucleic acid composition comprising: 1) a first nucleic acid comprising SEQ ID NO:4 and a second nucleic acid comprising SEQ ID NO:9; 2) a first nucleic acid comprising SEQ ID NO: 17 and a second nucleic acid comprising SEQ ID NO: 22; 3) a first nucleic acid comprising SEQ ID NO:30 and a second nucleic acid comprising SEQ ID NO:35; 4) a first nucleic acid comprising SEQ ID NO:42 and a second nucleic acid comprising SEQ ID NO:47; 5) a first nucleic acid comprising SEQ ID NO:55 and a second nucleic acid comprising SEQ ID NO:60; 6) a first nucleic acid comprising SEQ ID NO: 102 and a second nucleic acid comprising SEQ ID NO: 105; 7) a first nucleic acid comprising SEQ ID NO: 102 and a second nucleic acid comprising SEQ ID NO: 106; 8) a first nucleic acid comprising SEQ ID NO: 103 and a second nucleic acid comprising SEQ ID NO: 105; 9) a first nucleic acid comprising SEQ ID NO: 103 and a second nucleic acid comprising SEQ ID NO: 106; 10) a first nucleic acid comprising SEQ ID NO: 104 and a second nucleic acid comprising SEQ ID NO: 105; 11) a first nucleic acid comprising SEQ ID NO: 104 and a second nucleic acid comprising SEQ ID NO: 106; 12) a first nucleic acid comprising SEQ ID NO: 107 and a second nucleic acid comprising SEQ ID NO: 110; 13) a first nucleic acid comprising SEQ ID NO: 107 and a second nucleic acid comprising SEQ ID NO: 111; 14) a first nucleic acid comprising SEQ ID NO: 108 and a second nucleic acid comprising SEQ ID NO: 110; 15) a first nucleic acid comprising SEQ ID NO: 108 and a second nucleic acid comprising SEQ ID NO: 111; 16) a first nucleic acid comprising SEQ ID NO: 109 and a second nucleic acid comprising SEQ ID NO: 110; 17) a first nucleic acid comprising SEQ ID NO: 109 and a second nucleic acid comprising SEQ ID NO: 111; 18) a first nucleic acid comprising SEQ ID NO: 116 and a second nucleic acid comprising SEQ ID NO: 110; 19) a first nucleic acid comprising SEQ ID NO: 116 and a second nucleic acid comprising SEQ ID NO: 111; 20) a first nucleic acid comprising SEQ ID NO: 117 and a second nucleic acid comprising SEQ ID NO: 110; 21) a first nucleic acid comprising SEQ ID NO: 117 and a second nucleic acid comprising SEQ ID NO: 111; 22) a first nucleic acid comprising SEQ ID NO: 112 and a second nucleic acid comprising SEQ ID NO: 114; 23) a first nucleic acid comprising SEQ ID NO: 112 and a second nucleic acid comprising SEQ ID NO: 115; 24) a first nucleic acid comprising SEQ ID NO: 113 and a second nucleic acid comprising SEQ ID NO: 114; 25) A first nucleic acid comprising SEQ ID NO:113 and a second nucleic acid comprising SEQ ID NO:

115.

17. 1. An expression vector composition for encoding an isolated antibody or antigen-binding fragment thereof that specifically binds to CD73, comprising: (I) a first expression vector comprising a nucleotide sequence selected from the group consisting of SEQ ID NOs: 42, 102, 103, and 104; and a second expression vector comprising a nucleotide sequence selected from the group consisting of SEQ ID NOs: 47, 105, and 106; (II) a first expression vector comprising the nucleotide sequence of SEQ ID NO:4; and a second expression vector comprising the nucleotide sequence of SEQ ID NO:9; (III) a first expression vector comprising the nucleotide sequence of SEQ ID NO: 17; and a second expression vector comprising a nucleotide sequence selected from the group consisting of SEQ ID NOs: 22, 94, 95, and 96; (IV) a first expression vector comprising the nucleotide sequence of SEQ ID NO:30; and a second expression vector comprising the nucleotide sequence of SEQ ID NO:35; (V) a first expression vector comprising the nucleotide sequence of SEQ ID NO:55; and a second expression vector comprising the nucleotide sequence of SEQ ID NO:60; or (VI) a first expression vector comprising a nucleotide sequence selected from the group consisting of SEQ ID NOs: 107, 108, 109, 112, 113, 116, and 117; and a second expression vector comprising a nucleotide sequence selected from the group consisting of SEQ ID NOs: 110, 111, 114, and 115; Preferably An expression vector composition comprising: 1) a first expression vector comprising the nucleotide sequence of SEQ ID NO:4, and a second expression vector comprising the nucleotide sequence of SEQ ID NO:9; 2) a first expression vector comprising the nucleotide sequence of SEQ ID NO:17, and a second expression vector comprising the nucleotide sequence of SEQ ID NO:22; 3) a first expression vector comprising the nucleotide sequence of SEQ ID NO:30, and a second expression vector comprising the nucleotide sequence of SEQ ID NO:35; 4) a first expression vector comprising the nucleotide sequence of SEQ ID NO:42, and a second expression vector comprising the nucleotide sequence of SEQ ID NO:47; 5) a first expression vector comprising the nucleotide sequence of SEQ ID NO:55, and a second expression vector comprising the nucleotide sequence of SEQ ID NO:60; 6) a first expression vector comprising the nucleotide sequence of SEQ ID NO: 102, and a second expression vector comprising the nucleotide sequence of SEQ ID NO: 105; 7) a first expression vector comprising the nucleotide sequence of SEQ ID NO: 102, and a second expression vector comprising the nucleotide sequence of SEQ ID NO: 106; 8) a first expression vector comprising the nucleotide sequence of SEQ ID NO: 103, and a second expression vector comprising the nucleotide sequence of SEQ ID NO: 105; 9) a first expression vector comprising the nucleotide sequence of SEQ ID NO: 103, and a second expression vector comprising the nucleotide sequence of SEQ ID NO: 106; 10) a first expression vector comprising the nucleotide sequence of SEQ ID NO: 104, and a second expression vector comprising the nucleotide sequence of SEQ ID NO: 105; or 11) a first expression vector comprising the nucleotide sequence of SEQ ID NO: 104, and a second expression vector comprising the nucleotide sequence of SEQ ID NO: 106; 12) a first expression vector comprising the nucleotide sequence of SEQ ID NO: 107, and a second expression vector comprising the nucleotide sequence of SEQ ID NO: 110; 13) a first expression vector comprising the nucleotide sequence of SEQ ID NO: 107, and a second expression vector comprising the nucleotide sequence of SEQ ID NO: 111; 14) a first expression vector comprising the nucleotide sequence of SEQ ID NO: 108, and a second expression vector comprising the nucleotide sequence of SEQ ID NO: 110; 15) a first expression vector comprising the nucleotide sequence of SEQ ID NO: 108, and a second expression vector comprising the nucleotide sequence of SEQ ID NO: 111; 16) a first expression vector comprising the nucleotide sequence of SEQ ID NO: 109, and a second expression vector comprising the nucleotide sequence of SEQ ID NO: 110; 17) a first expression vector comprising the nucleotide sequence of SEQ ID NO: 109, and a second expression vector comprising the nucleotide sequence of SEQ ID NO: 111; 18) a first expression vector comprising the nucleotide sequence of SEQ ID NO: 116, and a second expression vector comprising the nucleotide sequence of SEQ ID NO: 110; 19) a first expression vector comprising the nucleotide sequence of SEQ ID NO:116, and a second expression vector comprising the nucleotide sequence of SEQ ID NO:111; 20) a first expression vector comprising the nucleotide sequence of SEQ ID NO:117, and a second expression vector comprising the nucleotide sequence of SEQ ID NO:110; 21) a first expression vector comprising the nucleotide sequence of SEQ ID NO:117, and a second expression vector comprising the nucleotide sequence of SEQ ID NO:111; 22) a first expression vector comprising the nucleotide sequence of SEQ ID NO:112, and a second expression vector comprising the nucleotide sequence of SEQ ID NO:114; 23) a first expression vector comprising the nucleotide sequence of SEQ ID NO:112, and a second expression vector comprising the nucleotide sequence of SEQ ID NO:115; 24) a first expression vector comprising the nucleotide sequence of SEQ ID NO:113, and a second expression vector comprising the nucleotide sequence of SEQ ID NO:114; 25) A first expression vector comprising the nucleotide sequence of SEQ ID NO:113, and a second expression vector comprising the nucleotide sequence of SEQ ID NO:

115.

18. 1. An expression vector encoding an isolated antibody or antigen-binding fragment thereof that specifically binds to CD73, comprising: (I) a first nucleic acid sequence comprising a nucleotide sequence selected from the group consisting of SEQ ID NOs: 42, 102, 103, and 104; and a second nucleic acid sequence comprising a nucleotide sequence selected from the group consisting of SEQ ID NOs: 47, 105, and 106; (II) a first nucleic acid sequence comprising the nucleotide sequence of SEQ ID NO:4; and a second nucleic acid sequence comprising the nucleotide sequence of SEQ ID NO:9; (III) a first nucleic acid sequence comprising the nucleotide sequence of SEQ ID NO: 17; and a second nucleic acid sequence comprising a nucleotide sequence selected from the group consisting of SEQ ID NOs: 22, 94, 95, and 96; (IV) a first nucleic acid sequence comprising the nucleotide sequence of SEQ ID NO:30; and a second nucleic acid sequence comprising the nucleotide sequence of SEQ ID NO:35; (V) a first nucleic acid sequence comprising the nucleotide sequence of SEQ ID NO:55; and a second nucleic acid sequence comprising the nucleotide sequence of SEQ ID NO:60; or (VI) a first nucleic acid sequence comprising a nucleotide sequence selected from the group consisting of SEQ ID NOs: 107, 108, 109, 112, 113, 116, and 117; and a second nucleic acid sequence comprising a nucleotide sequence selected from the group consisting of SEQ ID NOs: 110, 111, 114, and 115; or Preferably, An expression vector comprising: 1) a first nucleic acid sequence comprising the nucleotide sequence of SEQ ID NO:4 and a second nucleic acid sequence comprising the nucleotide sequence of SEQ ID NO:9; 2) a first nucleic acid sequence comprising the nucleotide sequence of SEQ ID NO:17 and a second nucleic acid sequence comprising the nucleotide sequence of SEQ ID NO:22; 3) a first nucleic acid sequence comprising the nucleotide sequence of SEQ ID NO:30 and a second nucleic acid sequence comprising the nucleotide sequence of SEQ ID NO:35; 4) a first nucleic acid sequence comprising the nucleotide sequence of SEQ ID NO:42 and a second nucleic acid sequence comprising the nucleotide sequence of SEQ ID NO:47; 5) a first nucleic acid sequence comprising the nucleotide sequence of SEQ ID NO:55 and a second nucleic acid sequence comprising the nucleotide sequence of SEQ ID NO:60; 6) a first nucleic acid sequence comprising the nucleotide sequence of SEQ ID NO: 102 and a second nucleic acid sequence comprising the nucleotide sequence of SEQ ID NO: 105; 7) a first nucleic acid sequence comprising the nucleotide sequence of SEQ ID NO: 102 and a second nucleic acid sequence comprising the nucleotide sequence of SEQ ID NO: 106; 8) a first nucleic acid sequence comprising the nucleotide sequence of SEQ ID NO: 103 and a second nucleic acid sequence comprising the nucleotide sequence of SEQ ID NO: 105; 9) a first nucleic acid sequence comprising the nucleotide sequence of SEQ ID NO: 103 and a second nucleic acid sequence comprising the nucleotide sequence of SEQ ID NO: 106; 10) a first nucleic acid sequence comprising the nucleotide sequence of SEQ ID NO: 104 and a second nucleic acid sequence comprising the nucleotide sequence of SEQ ID NO: 105; 11) a first nucleic acid sequence comprising the nucleotide sequence of SEQ ID NO: 104 and a second nucleic acid sequence comprising the nucleotide sequence of SEQ ID NO: 106; 12) a first nucleic acid sequence comprising the nucleotide sequence of SEQ ID NO: 107 and a second nucleic acid sequence comprising the nucleotide sequence of SEQ ID NO: 110; 13) a first nucleic acid sequence comprising the nucleotide sequence of SEQ ID NO: 107 and a second nucleic acid sequence comprising the nucleotide sequence of SEQ ID NO: 111; 14) a first nucleic acid sequence comprising the nucleotide sequence of SEQ ID NO: 108 and a second nucleic acid sequence comprising the nucleotide sequence of SEQ ID NO: 110; 15) a first nucleic acid sequence comprising the nucleotide sequence of SEQ ID NO: 108 and a second nucleic acid sequence comprising the nucleotide sequence of SEQ ID NO: 111; 16) a first nucleic acid sequence comprising the nucleotide sequence of SEQ ID NO: 109 and a second nucleic acid sequence comprising the nucleotide sequence of SEQ ID NO: 110; 17) a first nucleic acid sequence comprising the nucleotide sequence of SEQ ID NO: 109 and a second nucleic acid sequence comprising the nucleotide sequence of SEQ ID NO: 111; 18) a first nucleic acid sequence comprising the nucleotide sequence of SEQ ID NO: 116 and a second nucleic acid sequence comprising the nucleotide sequence of SEQ ID NO: 110; 19) a first nucleic acid sequence comprising the nucleotide sequence of SEQ ID NO:116 and a second nucleic acid sequence comprising the nucleotide sequence of SEQ ID NO:111; 20) a first nucleic acid sequence comprising the nucleotide sequence of SEQ ID NO: 117 and a second nucleic acid sequence comprising the nucleotide sequence of SEQ ID NO: 110; 21) a first nucleic acid sequence comprising the nucleotide sequence of SEQ ID NO:117 and a second nucleic acid sequence comprising the nucleotide sequence of SEQ ID NO:111; 22) a first nucleic acid sequence comprising the nucleotide sequence of SEQ ID NO: 112 and a second nucleic acid sequence comprising the nucleotide sequence of SEQ ID NO: 114; 23) a first nucleic acid sequence comprising the nucleotide sequence of SEQ ID NO: 112 and a second nucleic acid sequence comprising the nucleotide sequence of SEQ ID NO: 115; 24) a first nucleic acid sequence comprising the nucleotide sequence of SEQ ID NO: 113 and a second nucleic acid sequence comprising the nucleotide sequence of SEQ ID NO: 114; 25) A first nucleic acid sequence comprising the nucleotide sequence of SEQ ID NO:113 and a second nucleic acid sequence comprising the nucleotide sequence of SEQ ID NO:

115.

19. 19. A cell comprising the nucleic acid composition of claim 16, the expression vector composition of claim 17, or the expression vector of claim 18.

20. 20. A method for preparing an isolated antibody or antigen-binding fragment thereof described in any one of claims 1 to 5, comprising expressing the isolated antibody or antigen-binding fragment thereof in a cell described in claim 19, and isolating the isolated antibody or antigen-binding fragment thereof from the cell.

21. A kit comprising the isolated antibody or antigen-binding fragment thereof of any one of claims 1 to 5.

Images